Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptasel1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

```
                organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:22:56 ON 01 JUL 2008

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:23:14 ON 01 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 JUN 2008  HIGHEST RN 1031926-83-6
DICTIONARY FILE UPDATES:  30 JUN 2008  HIGHEST RN 1031926-83-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10552024s.str
```



chain nodes :
18 19 20 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
5-7 6-19 11-13 15-22 17-18 22-23 22-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 15-16 16-17
exact/norm bonds :
11-13 13-14 13-17 14-15 15-16 16-17 22-23 22-24
exact bonds :
5-7 6-19 15-22 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:Atom 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:23:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:23:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40 TO ITERATE

100.0% PROCESSED 40 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L3 9 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 12:23:35 ON 01 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Jul 2008 VOL 149 ISS 1
FILE LAST UPDATED: 30 Jun 2008 (20080630/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:952356 CAPLUS
DOCUMENT NUMBER: 141:379921
TITLE: Biaryl-substituted pyrazoles as sodium channel blockers, and their preparation, pharmaceutical compositions, and use in the treatment of pain
INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Tyagarajan, Sriram; Zhou, Xiahan
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092142	A1	20041028	WO 2004-US9713	20040330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004230854	A1	20041028	AU 2004-230854	20040330
CA 2520914	A1	20041028	CA 2004-2520914	20040330
EP 1615895	A1	20060118	EP 2004-759042	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1798738	A	20060705	CN 2004-80014916	20040330
JP 2006522178	T	20060928	JP 2006-509477	20040330
IN 2005DN04296	A	20070831	IN 2005-DN4296	20050922
ZA 200508575	A1	20060817	ZA 2005-8575	20051003
PRIORITY APPLN. INFO.:			US 2003-460109P	P 20030403
			WO 2004-US9713	W 20040330

OTHER SOURCE(S): MARPAT 141:379921
GI

AB Biaryl-substituted pyrazole compds., which are sodium channel blockers,

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

useful for the treatment of pain and other conditions, are disclosed. The compds. generally conform to the structure Ar1-Ar2-Ar3 [I; Ar1 = Ph with 0-3 selected substituents, typically H, Cl, CF3, OCF3, etc ; Ar2 = 1,3-phenylene, 2,5-, 2,4-, 2,6-, or 4,2-pyridinediyl, or 2,6-pyrazinediyl, all with 0-2 selected substituents, typically H, F, OCF3; Ar3 = pyrazol-1-yl or pyrazol-3(5)-yl, with 0-3 selected substituents, typically H, CO2H, CONH2, CO2Me, CO2Et, Me, etc.; including pharmaceutically acceptable salts]. Pharmaceutical compns. comprise an effective amt. of I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treatment of conditions, including acute pain, chronic pain, visceral pain, inflammatory pain, and neuropathic pain, comprise administering an effective amt. of I, either alone, or in combination with one or more therapeutically active compds. I displayed sodium channel blocking activity at concns. ranging from about <0.1 μM to about >50 μM in several described in vitro assays, e.g., in an electrophysiol. assay using an HEK-293 cell line stably expressing the PN1 sodium channel subtype. Approx 300 specific invention compds. were prepd. and listed individually in examples and/or claims. Several preps. are described in detail. For instance, invention compd. II was prepd in 4 steps. Thus, cyclocondensation of 3-BrC6H4NHNHC:NCl with Et 2,4-dioxovalerate in refluxing AcOH gave 94% Et 1-(3-bromophenyl)-5-methyl-1H-pyrazole-3-carboxylate. Alk. hydrolysis of this ester with 3N NaOH gave 89% of the corresponding acid, which was activated with 1,1-carbonyldiimidazole and amidated with NH4Cl to give 82% 1-(3-bromophenyl)-5-methyl-1H-pyrazole-3-carboxamide. Suzuki coupling of this bromide with 2-CF3OC6H4B(OH)2 (prepn. given) gave 88% II.

IT 784140-68-7P 784140-69-8P 784140-80-3P
784141-83-9P 784141-87-3P 784141-90-8P
784142-04-7P 784142-15-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of biaryl-substituted pyrazoles as sodium channel blockers, particularly as analgesics)

RN 784140-68-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-69-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

yl]-5-methyl- (CA INDEX NAME)

RN 784140-80-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4-fluoro-2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784141-83-9 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784141-87-3 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784141-90-8 CAPLUS

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784142-04-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)

RN 784142-15-0 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784142-18-3 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 1-[2',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    5.93      184.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                   -0.80       -0.80

FILE 'REGISTRY' ENTERED AT 12:23:43 ON 01 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 JUN 2008  HIGHEST RN 1031926-83-6
DICTIONARY FILE UPDATES:  30 JUN 2008  HIGHEST RN 1031926-83-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10552024.str
```



```
chain nodes :
18  19  20
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17
chain bonds :
5-7  11-13  15-18  18-19  18-20
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-17
14-15  15-16  16-17
```

```
exact/norm bonds :
11-13  13-14  13-17  14-15  15-16  16-17  18-19  18-20
exact bonds :
5-7  15-18
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:CLASS  19:CLASS
20:CLASS



L5      STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l5
SAMPLE SEARCH INITIATED 12:24:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       43 TO ITERATE

100.0% PROCESSED       43 ITERATIONS                                 9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:           467 TO      1253
PROJECTED ANSWERS:                9 TO       360

L6            9 SEA SSS SAM L5

=> s l5 ful
FULL SEARCH INITIATED 12:24:29 FILE 'REGISTRY'
```

FULL SCREEN SEARCH COMPLETED - 932 TO ITERATE

100.0% PROCESSED 932 ITERATIONS 150 ANSWERS
SEARCH TIME: 00.00.01

L7 150 SEA SSS FUL L5

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 362.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -0.80

FILE 'CAPLUS' ENTERED AT 12:24:31 ON 01 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Jul 2008 VOL 149 ISS 1
FILE LAST UPDATED: 30 Jun 2008 (20080630/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l7
L8 2 L7

=> d ibib abs hitstr tot

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:371226 CAPLUS
DOCUMENT NUMBER: 142:430266
TITLE: Preparation of substituted pyrazole ureas for the treatment of inflammation
INVENTOR(S): Clare, Michael; Fletcher, Theresa Reher; Hamper, Bruce

C.; Hanson, Gunnar A.; Beier, Richard F.; Huang, He; Lennon, Patrick J.; Okuru, David S.; Reding, Matthew T.; Stealey, Michael A.; Wolfson, Serge G.; Xie, Jin
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 420 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097797	A1	20051020	WO 2004-IB3388	20041015

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050197338 A1 20050908 US 2004-970769 20041021
PRIORITY APPLN. INFO.: US 2003-512848P P 20031021

OTHER SOURCE(S): CASREACT 142:430266; MARPAT 142:430266
CI

AB Title compds. I [X1-2 = O, S, amino; A = cycloalk(en)yl, heterocycloalkyl; etc., R = hydrido, L1R3; L1-2 = bond, O, SO, etc.; R1 = hydrido, CN, alkyl, alkenyl, etc.; R2-2a-3 = hydrido, OH, amino, etc.; R4a = hydrido, OH, alkoxy, alkyl, etc.; R4 = hydrido, OH, amino, hydroxyalkyl, etc.; R5 = alkyl, cycloalkyl, cycloalkenyl, etc.) are prepared For instance,

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

4-[(aminocarbonyl)amino]-1-(4-bromo-3-(trifluoromethyl)phenyl)-1H-pyrazole-5-carboxamide (II) is prepd. in 5 steps from 4-bromo-3-(trifluoromethyl)aniline, cyanoacetamide, Et bromoacetate and potassium cyanate. II has IC50 = 0.797 μM for hIKK-2. I are useful in the treatment of inflammation, arthritis, cancer, asthma, etc.

IT 850725-43-0P
RL: PAC (Pharmacological activity); PCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted pyrazole ureas for treatment of inflammation)

RN 850725-61-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3'-(acetylamino)[1,1'-biphenyl]-3-yl]-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



IT 850725-27-8P 850725-29-0P 850725-32-5P
850725-33-6P 850725-34-7P 850725-35-8P
850725-36-9P 850725-37-0P 850725-38-1P
850725-39-2P 850725-40-5P 850725-41-6P
850725-43-8P 850725-44-9P 850725-45-0P
850725-46-1P 850725-47-2P 850725-48-3P
850725-50-7P 850725-56-3P 850725-57-4P
850725-58-5P 850725-59-6P 850725-60-9P
850725-62-1P 850725-63-2P 850725-64-3P
850725-65-4P 850725-66-5P 850725-67-6P
850725-68-7P 850725-69-8P 850725-70-1P
850725-71-2P 850725-72-3P 850725-73-4P
850725-74-5P 850725-75-6P 850725-76-7P
850725-77-8P 850725-78-9P 850725-79-0P
850726-60-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrazole ureas for treatment of inflammation)

RN 850725-27-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 850725-29-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-(cyanomethyl)[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-32-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-hydroxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-33-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 850725-34-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(3'-(hydroxymethyl)[1,1'-biphenyl]-2-yl)- (CA INDEX NAME)

RN 850725-35-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3'-amino[1,1'-biphenyl]-3-yl)-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



RN 850725-36-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-37-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-(aminomethyl)[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-38-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



RN 850725-39-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-amino[1,1'-biphenyl]-3-yl)-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



RN 850725-40-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[4'-(acetylamino)[1,1'-biphenyl]-3-yl]-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



RN 850725-41-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[(aminocarbonyl)amino]-1-[3',4'-dimethoxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-43-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[3-(aminocarbonyl)-4-[[(aminocarbonyl)amino]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 850725-44-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[(aminocarbonyl)amino]-1-[4'-[methylsulfonyl)amino][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

CN 1H-Pyrazole-3-carboxamide, 4-[[(aminocarbonyl)amino]-1-[3-[3,4-dihydro-4-methyl-2H-1,4-benzoxazin-6-yl]phenyl]- (CA INDEX NAME)



RN 850725-50-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[(aminocarbonyl)amino]-1-[3-[1H-indol-5-yl]phenyl]- (CA INDEX NAME)



RN 850725-56-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[(aminocarbonyl)amino]-1-[2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-57-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[(aminocarbonyl)amino]-1-[3'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-58-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[3-(aminocarbonyl)-4-[[(aminocarbonyl)amino]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 850725-45-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[aminocarbonyl)amino]-1-[3-(5-quinolinyl)phenyl]- (CA INDEX NAME)



RN 850725-46-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[(aminocarbonyl)amino]-1-[4'-(dimethylamino)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-47-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[aminocarbonyl)amino]-1-[3-(1,3-benzodioxol-5-yl)phenyl]- (CA INDEX NAME)

RN 850725-49-4 CAPLUS



RN 850725-59-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[aminocarbonyl)amino]-1-[4'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-60-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[aminocarbonyl)amino]-1-[4'-[(propylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-62-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[aminocarbonyl)amino]-1-[3'-amino-4'-methyl[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-43-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-(aminomethyl)[1,1'-biphenyl]-2-yl]- (CA INDEX NAME)



RN 850725-44-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-45-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[(cyclopropylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-46-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-[(cyclopropylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-47-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-[[(2-

cyanoethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-48-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-49-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[[(2-cyanoethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-70-1 CAPLUS
CN Glycine, N-[[3'-[3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H-pyrazol-1-yl][1,1'-biphenyl]-4-yl]carbonyl]- (CA INDEX NAME)



RN 850725-71-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[2'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-72-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[2'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-73-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(2'-methoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-74-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-hydroxy-2'-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-75-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[(4-oxo-1-piperidinyl)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-76-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-acetyl[1,1'-biphenyl]-3-yl]-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



RN 850725-77-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-fluoro-2'-hydroxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-78-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(5'-fluoro-2'-hydroxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-79-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)-5'-fluoro[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 854732-60-2 CAPLUS
CN 1H-Pyrazole-7-carboxamide, 6-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:902356 CAPLUS
DOCUMENT NUMBER: 141:379921
TITLE: Biaryl-substituted pyrazoles as sodium channel blockers, and their preparation, pharmaceutical compositions, and use in the treatment of pain
INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Thangaraj, Sriram; Zhou, Sishan
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092140	A1	20041028	WO 2004-US9713	20040330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2004238054	A1	20041028	AU 2004-238054	20040330
CA 2528904	A1	20041028	CA 2004-2528904	20040330
EP 1618095	A1	20060118	EP 2004-759063	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
CN 1798738	A	20060705	CN 2004-80019416	20040330
JP 2006532196	T	20060928	JP 2006-509477	20040330
IN 2005DN04296	A	20070831	IN 2005-DN4296	20050922
US 20060167705	A1	20060727	US 2005-552824	20051007
PRIORITY APPLN. INFO.:			US 2003-460106P	P 20030403
			WO 2004-US9713	W 20040330

OTHER SOURCE(S): MARPAT 141:379921
GI



AB Biaryl-substituted pyrazole compds., which are sodium channel blockers,

useful for the treatment of pain and other conditions, are disclosed. The compds. generally conform to the structure Ar1-Ar2-Ar3 [I; Ar1 = Ph with 0-3 selected substituents, typically R, Cl, CF3, OCF3, etc.; Ar2 = 1,3-phenylene, 3,5-, 2,4-, 2,6-, or 4,2-pyridinediyl, or 2,6-pyrazinediyl, all with 0-2 selected substituents, typically R, CONR2, CONH2, CO2Me, CO2Et, Me, etc.; including pharmaceutically acceptable salts]. Pharmaceutical compns. comprise an effective amt. of I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treatment of conditions, including acute pain, chronic pain, visceral pain, inflammatory pain, and neuropathic pain, comprise administering an effective amt. of I, either alone, or in combination with one or more therapeutically active compds. I displayed sodium channel blocking activity at concns. ranging from about <0.1 μM to about <50 μM in several described in vitro assays, e.g., in an electrophysiol. assay using an HEK-293 cell line stably expressing the SCN1 sodium channel subtype. Approx 200 specific invention compds. were prepd. and listed individually in examples and/or claims. Several preps. are described in detail. For instance, invention compd. II was prepd in 4 steps. Thus, cyclopentenedetone of 3-BrC6H4NHNH2.HCl with Et 2,4-dioxovalerate in refluxing AcOH gave 86% Et 1-(3-bromophenyl)-5-methyl-1H-pyrazole-3-carboxylate. Alk. hydrolysis of this ester with 2N NaOH gave 89% of the corresponding acid, which was activated with 1,1-carbonyldiimidazole and amidated with NH4Cl to give 82% 1-(3-bromophenyl)-5-methyl-1H-pyrazole-3-carboxamide. Suzuki coupling of this bromide with 2-(CF2OC6H4B(OH)2 [prepn. given] gave 80% II.

IT 784140-04-8, 5-Methyl-1'-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784140-05-9P, 5-tert-Butyl-1-(2'-chloro-2,1'-biphenyl-3-yl)-1H-pyrazole-3-carboxamide 784140-08-2P, 1-(4'-Fluoro-2'-(trifluoromethyl)-1,1'-biphenyl-3-yl)-5-methyl-1H-pyrazole-3-carboxamide 784140-09-3P 784140-17-4P 784140-24-7P 784140-30-3P 784140-31-4P 784140-32-5P 784140-33-6P 784140-34-7P 784140-35-8P 784140-36-9P 784140-37-0P 784140-38-1P 784140-39-2P 784140-40-5P 784140-41-6P 784140-42-7P 784140-43-8P 784140-44-9P 784140-45-0P 784140-46-1P 784140-47-2P 784140-48-3P 784140-49-4P 784140-50-7P 784140-51-8P 784140-52-9P 784140-53-0P 784140-54-1P 784140-55-2P 784140-56-3P 784140-57-4P 784140-58-5P 784140-59-6P 784140-60-9P 784140-61-0P 784140-62-1P 784140-63-2P 784140-64-3P 784140-65-4P 784140-66-5P 784140-67-6P 784140-68-7P 784140-69-8P 784140-70-1P 784140-71-2P 784140-72-3P 784140-73-4P 784140-74-5P 784140-75-6P 784140-76-7P 784140-77-8P 784140-78-9P 784140-79-0P 784140-80-3P 784140-81-4P 784140-82-5P 784140-83-6P 784140-84-7P 784140-85-8P 784140-86-9P 784140-87-0P 784140-88-1P 784140-89-2P 784140-90-5P 784140-91-6P 784140-92-7P 784140-93-8P 784140-94-9P 784140-95-0P 784140-96-1P 784140-97-2P 784140-98-3P 784140-99-4P 784141-00-0P, 5-Methyl-1-(3-(quinolin-8-yl)phenyl)-1H-pyrazole-3-carboxamide 784141-01-1P, 5-Methyl-1-(3-(benzo[b]thien-7-yl)phenyl)-1H-pyrazole-3-carboxamide 784141-02-2P,

5-Methyl-1-[3-(quinolin-6-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-04-4P, 5-Methyl-1-[3-(5-methylquinolin-8-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-05-5P, 5-Methyl-1-(3-(isoquinolin-5-yl)phenyl)-1H-pyrazole-3-carboxamide 784141-06-6P, 5-Methyl-1-[3-(quinolin-5-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-07-7P, 5-Methyl-1-[3-(naphthalen-1-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-08-8P, 5-Methyl-1-[3-[1-(tert-butoxycarbonyl)-1H-indol-5-yl]phenyl]-1H-pyrazole-3-carboxamide 784141-09-9P, 5-Methyl-1-(3',4',5'-trimethoxy-1,1'-biphenyl-3-yl)-1H-pyrazole-3-carboxamide 784141-10-2P, 5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-11-3P, 5-Methyl-1-[5'-(2,2-difluorobenzo[1,3]dioxol-4-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-55-5P, 4-Bromo-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-65-7P, 1-(4-Fluoro-2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl)-5-methyl-1H-pyrazole-3-carboxamide 784141-79-9P, 1-[2'-(Trifluoromethoxy)biphenyl-3-yl]-1H-pyrazole-3,5-dicarboxamide 784141-90-0P, Ethyl 5-methoxymethyl-1-[2'-(trifluoromethoxy)biphenyl-3-yl]-1H-pyrazole-5-carboxylate 784141-92-2P 784141-93-3P 784141-94-4P 784141-85-1P 784141-86-2P 784141-87-3P 784141-88-4P 784141-89-5P 784141-76-8P 784141-91-9P 784141-92-0P 784141-93-1P 784141-94-2P 784141-95-3P 784141-96-4P 784141-99-7P 784142-00-3P 784142-03-6P 784142-04-7P 784142-08-1P 784142-10-5P 784142-14-9P 784142-15-0P 784142-17-2P 784142-18-3P 784142-21-8P 784142-22-9P 784142-25-2P 784142-26-3P 784142-27-4P 784142-28-5P 784142-29-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of biaryl-substituted pyrazoles as sodium channel blockers, particularly as analgesics)

RN 784140-04-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-05-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2'-chloro[1,1'-biphenyl]-3-yl)-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 784140-09-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-16-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-chloro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-17-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-26-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-hydroxy[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-34-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-35-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3',5'-dichloro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-36-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3'-fluoro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-37-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-30-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 784140-31-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2'-formyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-32-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2',4'-dichloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-33-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-38-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-39-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-chloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-40-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-fluoro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-41-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3',4'-dichloro[1,1'-biphenyl]-3-yl)-5-methyl-



RN 784140-42-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',3'-dimethoxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-43-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3'-chloro-2'-methyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-44-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[5'-chloro-2'-methoxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)

RN 784140-45-0 CAPLUS



RN 784140-49-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-52-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[1,1'-biphenyl]-3-yl-5-methyl- (CA INDEX NAME)



RN 784140-53-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-(2'-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 784140-46-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-47-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[1,1':3',1''-terphenyl]-3-yl- (9CI) (CA INDEX NAME)



RN 784140-48-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-[(4-oxo-1-piperidinyl)methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784140-52-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[3-(aminocarbonyl)-5-methyl-1H-pyrazol-1-yl]-2-methyl- (CA INDEX NAME)



RN 784140-53-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3'-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-54-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-(4'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 784140-55-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3'-chloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)

RN 784140-56-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-57-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-fluoro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-58-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-ethoxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-59-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2',4'-difluoro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-60-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-65-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2',3'-dimethyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-66-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[3-(aminocarbonyl)-5-methyl-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 784140-67-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-formyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-68-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',4'-bis[trifluoromethyl)][1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-61-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-(1,1-dimethylethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-62-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-63-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-64-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-69-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-70-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-fluoro-6'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-71-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-72-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-chloro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-73-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-74-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-76-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-79-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2',3'-dichloro-4-fluoro[1,1'-biphenyl]-3-yl)-

CN 1H-Pyrazole-3-carboxamide, 5-[1,1-dimethylethyl]-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-96-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2',4'-dichloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-99-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-chloro-6'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784141-00-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(8-quinolinyl)phenyl]- (CA INDEX NAME)



5-methyl- (CA INDEX NAME)



RN 784140-80-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4-fluoro-2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-82-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(5'-fluoro-2'-hydroxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-83-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[5'-(dimethylamino)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-89-2 CAPLUS

RN 784141-01-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3-benzo[b]thien-7-ylphenyl)-5-methyl- (CA INDEX NAME)



RN 784141-02-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(6-quinolinyl)phenyl]- (CA INDEX NAME)



RN 784141-04-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(3-methyl-8-quinolinyl)phenyl]- (CA INDEX NAME)



RN 784141-05-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3-(5-isoquinolinyl)phenyl]-5-methyl- (CA INDEX NAME)

RN 784141-96-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(5-quinolinyl)phenyl]- (CA INDEX NAME)



RN 784141-97-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(1-naphthalenyl)phenyl]- (CA INDEX NAME)



RN 784141-98-8 CAPLUS
CN 1H-Indole-1-carboxylic acid, 5-[3-[[3-(aminocarbonyl)-1-methyl-1H-pyrazol-5-yl]phenyl]-, 2,1-dimethylethyl ester (CA INDEX NAME)



RN 784141-55-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-68-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784141-79-3 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-80-6 CAPLUS



RN 784141-09-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 784141-10-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-(difluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784141-11-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[5-(2,2-difluoro-1,3-benzodioxol-4-yl)phenyl]-5-methyl- (CA INDEX NAME)



RN 784141-82-8 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-83-9 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-84-0 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-85-1 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(trifluoromethoxy)-5'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-96-2 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(difluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-87-3 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-91-9 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(1-methylethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-92-0 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(2,2,3,3,3-pentafluoropropoxy)-3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-93-1 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(2,2,3,3,3-pentafluoropropoxy)-3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784141-98-4 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-fluoro-6'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-89-5 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[4'-fluoro-2'-(2,2,3,3,3-pentafluoropropoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-90-8 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-94-2 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[5'-fluoro-2'-(2,2,3,3,3-pentafluoropropoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-95-3 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[5'-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-96-4 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[4'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784143-99-7 CAPLUS
CN 1H-Pyrazole-5,5-dicarboxamide, 1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-00-3 CAPLUS
CN 1H-Pyrazole-5,5-dicarboxamide, N5-ethyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-03-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784142-04-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784142-08-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-10-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-14-9 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-15-0 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-17-2 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-18-3 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 1-[2',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-21-8 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 1-[2',6-bis(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-22-9 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 5-methyl-1-[6-(trifluoromethoxy)-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-25-2 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-(aminocarbonyl)-1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl-, ethyl ester (CA INDEX NAME)



RN 784142-26-3 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-27-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-(aminocarbonyl)-1-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl-, ethyl ester (CA INDEX NAME)



RN 784142-28-5 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 1-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-35-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-amino-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    12.82      375.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    -1.60       -2.40

FILE 'REGISTRY' ENTERED AT 12:26:52 ON 01 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 JUN 2008  HIGHEST RN 1031926-83-6
DICTIONARY FILE UPDATES:  30 JUN 2008  HIGHEST RN 1031926-83-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10552024b.str
```



```
chain nodes :
18  19
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17
chain bonds :
5-7  11-13  15-18  18-19
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-17
14-15  15-16  16-17
```

```
exact/norm bonds :
11-13  13-14  13-17  14-15  15-16  16-17  18-19
exact bonds :
5-7  15-18
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:CLASS  19:CLASS



L9      STRUCTURE UPLOADED

=> d
L9 HAS NO ANSWERS
L9              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l9
SAMPLE SEARCH INITIATED 12:27:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       65 TO ITERATE

100.0% PROCESSED       65 ITERATIONS                                 11 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          817 TO     1783
PROJECTED ANSWERS:              22 TO      418

L10          11 SEA SSS SAM L9

=> s l9 ful
FULL SEARCH INITIATED 12:27:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1386 TO ITERATE
```

100.0% PROCESSED 1386 ITERATIONS 207 ANSWERS
SEARCH TIME: 00.00.01

L11 207 SEA SSS FUL L9

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 554.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -2.40

FILE 'CAPLUS' ENTERED AT 12:27:12 ON 01 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Jul 2008 VOL 149 ISS 1
FILE LAST UPDATED: 30 Jun 2008 (20080630/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l11
L12 2 L11

=> fil reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.48 554.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -2.40

FILE 'REGISTRY' ENTERED AT 12:27:16 ON 01 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JUN 2008 HIGHEST RN 1031926-83-6
DICTIONARY FILE UPDATES: 30 JUN 2008 HIGHEST RN 1031926-83-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10552024c.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
5-7 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 15-16 16-17
exact/norm bonds :
11-13 13-14 13-17 14-15 15-16 16-17
exact bonds :
5-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom

```
L13     STRUCTURE UPLOADED

=> d
L13 HAS NO ANSWERS
L13              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l13
SAMPLE SEARCH INITIATED 12:27:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      213 TO ITERATE

100.0% PROCESSED      213 ITERATIONS                              21 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:          3385 TO     5135
PROJECTED ANSWERS:              146 TO      694

L14          21 SEA SSS SAM L13

=> s l13 ful
FULL SEARCH INITIATED 12:27:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4148 TO ITERATE

100.0% PROCESSED     4148 ITERATIONS                             354 ANSWERS
SEARCH TIME: 00.00.01

L15         354 SEA SSS FUL L13

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     732.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -2.40
```

FILE 'CAPLUS' ENTERED AT 12:27:46 ON 01 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Jul 2008 VOL 149 ISS 1
FILE LAST UPDATED: 30 Jun 2008 (20080630/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l15
L16 48 L15

=> d ibib abs hitstr tot
THE ESTIMATED COST FOR THIS REQUEST IS 261.60 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

ACCESSION NUMBER: 2008:673581 CAPLUS
TITLE: Preparation of heteroaryl amides as type I glycine transport inhibitors
INVENTOR(S): Lowe, John Adams, III; Sakya, Subas Man; Sanner, Mark Allen; Coe, Jotban Wadsworth; McEarly, Stanton Furst
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 536pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008067509	A2	20080605	WO 2007-IB3604	20071119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BW, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GH, GM, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:		US 2006-867895P	P 20061130	

GI



AB The title compds. I [HET = (un)substituted 5-6 membered heteroaryl; X1 = C(O) or SO2; X2 = (C0-C10 alkylene)-Oy-(C0-C10 alkylene), (C3-C10



RN 1031326-92-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

RN 1031326-99-4 CAPLUS
CN 1H-Imidazole-4-sulfonamide, N-[4-aminocyclohexyl]-N-[(3*-(3,5-difluoro[1,1'-biphenyl]-4-yl]methyl]-1-methyl- (CA INDEX NAME)

RN 1031327-13-5 CAPLUS
CN 1H-Imidazole-4-sulfonamide, N-[4-aminocyclohexyl]-1-methyl-N-[(3*-(1H-pyrazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

cycloalkyl)-(C0-C10 alkylene)-Oy-(C0-C10 alkylene); y = 0-1; X3 = (C0-C10 alkylene)-NHR2, (C3-C10 cycloalkyl)-(C0-C10 alkylene)-NHR2, (C0-C10 alkylene)-X4 or (C3-C10 cycloalkyl)-(C0-C10 alkylene)-X4 (wherein cycloalkyl is optionally substituted by one or more OH); X4 = N-containg heterocycloalkyl or N- containg heteroaryl; ring A = (un)substituted (heteroaryl or heterocycloalkyl; R1, R2 = H, alkyl, alkenyl, etc.; with the proviso] that exhibit activity as glycine transport inhibitors, and are useful for the enhancement of cognition and the treatment of the pos... and neg. symptoms of schizophrenia and other psychoses in mammals, including humans, were prepd. Over three-thousand compds. I were prepd. E.g., a multi-step synthesis of II, starting from 1,4-dioxaspiro[4.5]decan-8-one with 3-trifluoromethoxybenzylamine, was given. The exemplified compds. I were tested in the Gly1 radioligand binding assay (data given for most of the compds. I). Pharmaceutical compns. comprising the compd. I alone or in combination with other therapeutic agents are disclosed.

IT 1031326-48-7P 1031326-49-8P 1031326-92-7P
1031326-99-4P 1031327-13-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heteroaryl amides as type I glycine transport inhibitors useful for treating diseases)

RN 1031321-41-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-(4-aminocyclohexyl)-1-methyl-N-[1,2,3,4-tetrahydro-4-[5-(1H-pyrazol-1-yl)phenyl]-2-naphthalenyl]- (CA INDEX NAME)



RN 1031326-48-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

ACCESSION NUMBER: 2007:1455859 CAPLUS
DOCUMENT NUMBER: 148:79071
TITLE: Preparation of (hetero)aryl substituted acylguanidines as renin inhibitors
INVENTOR(S): Boeckler, Jozsef Szolt; McCort, Gary; Thiera, Berangere; Matter, Hans; Steinhagen, Henning
PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.
SOURCE: PCT Int. Appl., 139pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007144769	A2	20071221	WO 2007-IB2591	20070613
WO 2007144769	A3	20080320		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, MD, RU, TJ, TM, AP, EA, EP, OA			
PRIORITY APPLN. INFO.:			EP 2006-290979 A	20060615

OTHER SOURCE(S): MARPAT 148:79071
GI





ACCESSION NUMBER: 2007:1178736 CAPLUS
DOCUMENT NUMBER: 147:522268
TITLE: Aminoethylamino-aryl (AXAA) compounds as FKD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of FKD-mediated diseases
INVENTOR(S): Kaynham, Tony Michael; Hammonds, Timothy Robin; Gilliart, Julia Helen; Charles, Mark David; Fave, Gregoire Alexandre; Foston, Caroline Heather; Carr, James Lindsay; Mistry, Neela Sunit
PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK
SOURCE: PCT Int. Appl., 300pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007125331	A2	20071108	WO 2007-GB1537	20070426
WO 2007125331	A3	20080103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, MD, RU, TJ, TM, AP, EA, EP, OA			
PRIORITY APPLN. INFO.:			GB 2006-8289 A	20060426
			US 2006-745830P P	20060426

OTHER SOURCE(S): MARPAT 147:522268
GI

AB The title compds. I [wherein A = benzene ring, heteroaryl, or cycloalkyl; Q = O or CH2; X-S = independently CH or N; R1 and R2 = independently H, halo, hydroxy, cyano, nom. CF3, etc.; R3 = (un)substituted alkyl; R4 = H, halo, hydroxy, cyano, alkyl, or alkoxy; R5 and R6 = independently H, halo, alkyl; or R5 and R6 form a ring; R7 and R8 = independently H or alkyl; or R7 and R8 form a ring; R9 and R10 = independently H, hydroxy, alkylcarbonyl, or alkoxyarbonyl; or R9 and R10 form an (un)substituted ring; R11 = H or (un)substituted (cyclo)alkyl; or salts with pharmaceutically acceptable acids or bases, hydrates, or solvates thereof were prepared as renin inhibitors. For example, II•HCl was prepared in a multi-step synthesis. Most of the compds. showed inhibitory activity with IC50 of 0.001-10 μM against recombinant human renin. Formulations as tablets were described. The compds. are useful for the treatment and prevention of hypertension, heart failure, cardiac infarction, etc. (no data).

IT 960407-41-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (hetero)aryl substituted acylguanidines as renin inhibitors)

RN 960407-41-4 CAPLUS
CN [1,1'-Biphenyl]-4-propanamide, N-[aminoiminomethyl]-2-(3-methoxypropoxy)-3'-(1H-pyrazol-1-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 960407-40-3
CMF C23 H27 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



AB The invention pertains generally to the field of therapeutic compds. of formula I, and more specifically to certain aminoethylamino-aryl (AXAA) compds. which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The invention also pertains to pharmaceutical compns. comprising such compds., and the use of compds. of formula I and compns., both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc. Compds. of formula I wherein J as N and CH; R1, R2, R3, R4, R5, R6 and R7 are independently H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, etc.; R8 and R9 are independently H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, etc.; RRR9 taken together form a 5- and 6-membered ring containing 1-3 nitrogens; R10, R11, R12 and R13 are independently H, Cl-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, etc.; and their pharmaceutically acceptable salts, solvates, hydrates, ethers, esters, chemical protected forms and prodrugs thereof, are claimed. Example compound II was prepared by cross-coupling of [2-(2-chloro-7-trifluoromethylquinazolin-4-ylamino)-ethyl]carbamic acid tert-Bu ester with 2-hydroxyphenylboronic acid followed by hydrolysis. All the invention compds. were evaluated for their PKD inhibitory activity (sons data given).

IT 956124-76-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminoethylamino-aryl compds. as protein kinase D inhibitors useful in treatment of PKD-mediated diseases)

RN 956124-76-8 CAPLUS
CN [1,1'-Biphenyl]-4-ol, 3-[4-[[(2R)-2-aminobutyl]methylamino]-2-pyrimidinyl]-3'-(1H-pyrazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 2007:1068976 CAPLUS
DOCUMENT NUMBER: 147:385823
TITLE: Tetralimes as H3 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of histamine H3 receptor mediated diseases
INVENTOR(S): McGeady, Stanton Furst; Parikh, Vinod Dipat
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 79pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007109057	A2	20070920	WO 2007-US6556	20070301
WO 2007109057	A3	20071206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-782164P P 20060313

OTHER SOURCE(S): MARPAT 147:385823
GI





AB This invention as directed to a compound of formula I, or a pharmaceutically
acceptable salt thereof; a pharmaceutical composition containing a compound of
formula I a process of preparation of a compound of formula I, a method of
treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mamal in
need of such treatment a compound of formula I, and a method of treatment of
a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion
sickness, respiratory diseases, allergy, allergy- induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract,
hyper and hypo motility and acidic secretion of the gastro- intestinal tract, the method comprising administering to a mamal in need of such treatment a compound of formula I. Compds. of formula I wherein X, Y, Q and
X are independently N and C; R1 and R2 are independently H, C1-8 (halo)alkyl; (un)substituted C3-7 cycloalkyl-C0-4 alkyl; R1R2 taken together to form an (un)substituted 4- to 7-membered heterocycloalkyl; R3 is H, C1-6 alkyl, C1-6 alkoxy, halo, 5- to 6-membered (hetero)aryl; OH, CHCOR, CONR2 and derivs., and SO1-2-C1-4 alkyl; R7 is H; R3R7 taken together with two adjacent atoms in the ring comprising X, Y, Q and X to which they are attached, form an (un)substituted 5- to 6-membered heterocyclic ring; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cross-coupling of

1-(6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)pyrrolidine with 3-(dimethylaminocarbonyl)phenylboronic acid. All the invention compds. were evaluated for their H3 receptor antagonistic activity.

IT 950592-05-9P 950592-20-8P 950593-82-4P
950593-95-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of tetraline compds. as H3 receptor antagonists)

useful in treatment of diseases - mediated by histamine H3 receptors)

RN 950592-05-9 CAPLUS
CN 1H-Pyrazole, 3,5-dimethyl-1-[3-[5,6,7,8-tetrahydro-6-(1-pyrrolidinyl)-2-naphthalenyl]phenyl]- (CA INDEX NAME)



RN 950592-20-8 CAPLUS
CN 1H-Pyrazole, 1-[3-[5,6,7,8-tetrahydro-6-(1-pyrrolidinyl)-2-naphthalenyl]phenyl]- (CA INDEX NAME)



RN 950593-82-4 CAPLUS
CN 1H-Pyrazole, 1-[3-[5,6,7,8-tetrahydro-6-(2-methyl-1-pyrrolidinyl)-2-naphthalenyl]phenyl]- (CA INDEX NAME)



RN 950593-95-0 CAPLUS
CN 1H-Pyrazole, 3,5-dimethyl-1-[3-[5,6,7,8-tetrahydro-6-(2-methyl-1-pyrrolidinyl)-2-naphthalenyl]phenyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 5 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:912405 CAPLUS
DOCUMENT NUMBER: 147:277591
TITLE: Preparation of 1-pyrazolyl-3-phenylurea p38 MAP kinase
inhibitors as antiinflammatory medicaments
INVENTOR(S): Flynn, Daniel L.; Petillo, Peter A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 283pp., Cont.-in-part of U.S. Ser. No. 864,329.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070191376	A1	20070816	US 2004-12395	20041223
US 20040180906	A1	20040916	US 2003-746440	20031224
US 7144911	B2	20061205		
US 20050188286	A1	20051229	US 2004-864329	20040604
US 7202257	B2	20070410		
PRIORITY APPLN. INFO.:			US 2003-746440	A2 20031224
			US 2004-864329	A2 20040604
			US 2002-437904P	P 20021231
			US 2002-437905P	P 20021231
			US 2002-437915P	P 20021231
			US 2002-437487P	P 20021231
			US 2003-463804P	P 20030418

OTHER SOURCE(S): MARPAT 147:277591
GI



AB Title compds. [R1X]mA[NR]pLn[NH]pDIqYtQ [I; wherein R1 = (un)substituted (hetero)aryl; X, Y = independently O, S, NR6, NR6SO2, NR6CO, alkynyl, alkenyl, alkylene, O(CR2)h, NR6(CR2)h, wherein for each alkylene, O(CR2)h, and NR6(CR2)h, one of the methylene groups may be substituted with CO; h =

L16 ANSWER 5 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

1-4; A = (un)substituted aryl, hetero(bi)cyclyl; D = (un)substituted Ph, pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, pyrimidyl; E = (un)substituted Ph, pyridinyl, pyrimidinyl; L = CO, SO2, n, s, p, q, t = independently 0, 1; Q = (un)substituted heterocyclyl, Ph, etc.; R6 = independently H, alkyl, allyl, 7MS(CH2)2, with exceptions] were prepd. as p38 MAP kinase inhibitors. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the a-C helix, the a-D helix, the catalytic loop, the switch control ligand sequence, or the C-lobe residues of the kinase protein with I (no data). Although the methods of preps. are not claimed, preps. and/or characterization data for over 500 examples of I and many intermediates are included. For example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester using 10% Pd/C in EtOH provided the propionate, which was treated with NaNO2 in the presence of 6N HCl and SnCl2•2H2O to give the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentanenitrile in EtOH and 6N HCl afforded Me 3-(3-(5-tert-butyl-2-amino-1H-pyrazole-1-yl)phenyl)propionate. Coupling of the amine with 1-naphthyl isocyanate in CH2Cl2, followed by redn. with LiAlH in THF/MeOH/H2O provided the urea II. In a competition assay with SKF 86002 as a fluorescent probe, the latter inhibited p38 MAP kinase with IC50 of 45 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a wide variety of inflammatory conditions (no data).

IT 725686-39-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of (pyrazolyl)(aryl)urea p38 kinase inhibitors as antiinflammatory agents)

RN 725686-39-5 CAPLUS

CN 1H-Pyrazol-5-amine, 1-[1,1'-biphenyl]-3-yl-3-(1,1-dimethylethyl)- (CA INDEX NAME)



IT 725686-40-8P 725686-41-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of (pyrazolyl)(aryl)urea p38 kinase inhibitors as antiinflammatory agents)

RN 725686-40-8 CAPLUS

CN Urea, N-[1-[1,1'-biphenyl]-3-yl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)

L16 ANSWER 5 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 725686-41-9 CAPLUS

CN Urea, N-[1-[1,1'-biphenyl]-3-yl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-(4-chlorophenyl)- (CA INDEX NAME)

ACCESSION NUMBER: 2007:874154 CAPLUS
DOCUMENT NUMBER: 147:257665
TITLE: Spirochromane derivatives as histamine H3 receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Butler, Todd William; Howard, Barry Ralph, Jr.; Wager, Travis T.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 41pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007089462	A1	20070809	WO 2007-US35	20070102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, ST, SV, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:			US 2006-764230P P	20060201

OTHER SOURCE(S): MARPAT 147:257665
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to spirochromane derivs. of formula I, which are histamine H3 receptor antagonists. In compds. I, R1 is selected from (un)substituted Ph, (un)substituted naphthyl, (un)substituted 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S, and (un)substituted carbanoyl; and R2 is C1-4 alkyl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound of formula I, and optionally a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of disorders or conditions that respond to H3 receptor antagonism, such as depression, anxiety disorders, and attention-deficit disorders. Cyclocondensation of 5'-bromo-2'-hydroxyacetophenone with N-Boc-piperidin-4-one followed by hydride reduction and deoxygenation yielded spirochromane II, which underwent alkylation with Et iodide and Suzuki

coupling with 2-methoxypyridine-5-boronic acid to give spirochromane III. The compds. of the invention, e.g., III, are antagonists of histamine H3 receptors (no data).
IT 945723-13-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of spirochromane derivs. as histamine H3 receptor antagonists)
RN 945723-13-7 CAPLUS
CN 3spiro[2H-1-benzopyran-2,4'-piperidine], 1'-ethyl-5,6-dihydro-6-[3-(2H-pyrazol-3-yl)phenyl]- (CA INDEX NAME)

ACCESSION NUMBER: 2007:762505 CAPLUS
DOCUMENT NUMBER: 147:186909
TITLE: Preparation of oxazolidinone compounds as CETP inhibitors
INVENTOR(S): Ali, Anyadi; Lu, Ehajian; Sinclair, Peter J.; Chen, Yi-Heng; Smith, Cameron J.; Li, Hong
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 214pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007079186	A2	20070712	WO 2006-US49494	20061229
WO 2007079186	A3	20071206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:			US 2005-7552849 P	20051230

OTHER SOURCE(S): MARPAT 147:186909
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Y = -CO-, -(CR3R3')- X = -O-, -NR-, -N(alkyl)-, etc.; Z = -CO-, -SO2-, -C(:NR)-; R9 = R, -CN, alkyl (optionally substituted with halo); R = R1, alkyl (optionally substituted with halo), halo; R = Q1, etc.; A3 = (a) aromatic ring selected from Ph and naphthyl, (b) Ph ring fused to non-aromatic cycloalkyl ring, which optionally comprises double bonds, (c) heterocyclic ring having heteroatom selected from N, S, O, etc., and optionally comprising double bonds and a carbonyl group, etc., R4 = alkyl, alkenyl, alkynyl, etc.; p = 0-4; R3 = H, alkyl (optionally substituted with halo), halo, etc.; R2 = H, alkyl (optionally substituted with halo), halo, etc.; R5 = H, -OH, alkyl (optionally substituted with halo), etc.; and their pharmaceutically acceptable salts], useful for raising HDL-cholesterol, lowering LDL-cholesterol, and for treating or preventing atherosclerosis, were prepared For example, a multi-step synthesis of II, starting from N-benzyloxycarbonyl-L-alanine, was given. Compds. in this invention were evaluated for their CETP inhibitory activity, and exhibited

IC50 values of less than or equal to 50 μM.
IT 943916-14-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinone compds. as CETP inhibitors for treatment of atherosclerosis)
RN 943916-14-1 CAPLUS
CN 2-Oxazolidinone, 5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-3-[[3'-[2S-pyrazol-3-yl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-, (4S,5R)- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 8 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:329596 CAPLUS
DOCUMENT NUMBER: 146:337728
TITLE: Preparation of arylmethoxypyrrolidines as inhibitors of norepinephrine and/or serotonin transporters.
INVENTOR(S): Letro, Thomas Bruno, Jr.; Lazerwith, Scott Edward; Sheehan, Susan Mary Kuit; Thomas, Anthony Jerome
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 65pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007021828	A2	20070222	WO 2006-IB2457	20060904
WO 2007021828	A3	20070712		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH
CA 2622222	A1	20070222	CA 2006-2622222	20060904
EP 1931653	A2	20080618	EP 2006-795438	20060904
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			US 2005-716708P	P 20050913
			WO 2006-IB2457	W 20060904

OTHER SOURCE(S): MARPAT 146:337728
AB ASCKSZKJH [R20 = (substituted) 3-pyrrolidinyl; J = O, NR22; R22 = H, alkyl, alkyloxoalkyl; S = (substituted) phenylene, naphthylene, heteroarylene, phiquilin [heteroarylene; A = (substituted) Ph, naphthyl, heteroaryl, heterocyclic (heteroaryl)] were prepared for treatment of e.g. attention deficit hyperactivity disorder, neurogenic pain, urinary incontinence, generalized anxiety disorder, depression, schizophrenia, and fibromyalgia. Thus, (S)-3-(4'-methylbiphenyl-2-ylmethoxy)pyrrolidine hydrochloride (preparation outlined) inhibited human norepinephrine transporter binding with Ki = 7.60 nM.
IT 929542-68-7P, (S)-1-[2'-(Pyrrolidin-3-yloxymethyl)biphenyl-3-yl]-1H-pyrazole 929542-71-4P, (S)-3,5-Dimethyl-1-[2'-(pyrrolidin-3-yloxymethyl)biphenyl-3-yl]-1H-pyrazole 929543-35-1P,

(S)-1-(4'-Fluoro-2'-(pyrrolidin-3-yloxymethyl)biphenyl-3-yl)-3,5-dimethyl-1H-pyrazole 929543-39-5P, (S)-1-(4'-Fluoro-2'-(pyrrolidin-3-yloxymethyl)biphenyl-3-yl)-1H-pyrazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L16 ANSWER 8 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 929543-39-5 CAPLUS
CN 1H-Pyrazole, 1-[4'-fluoro-2'-[[(3S)-3-pyrrolidinyloxy]methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 8 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Uses)
(preps. of arylmethoxypyrrolidines as inhibitors of norepinephrine and/or serotonin transporters)
RN 929542-68-7 CAPLUS
CN 1H-Pyrazole, 1-[2'-[[(3S)-3-pyrrolidinyloxy]methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929542-81-4 CAPLUS
CN 1H-Pyrazole, 3,5-dimethyl-1-[2'-[[(3S)-3-pyrrolidinyloxy]methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 929543-35-1 CAPLUS
CN 1H-Pyrazole, 1-[4'-fluoro-2'-[[(3S)-3-pyrrolidinyloxy]methyl][1,1'-biphenyl]-3-yl]-3,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 9 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:230757 CAPLUS
DOCUMENT NUMBER: 146:295915
TITLE: Preparation of pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
INVENTOR(S): Barmer, Bruce Lester; Balotta, Joseph Anthony; Potoski, Nadej; Gillespie, Paul; Goodrow, Robert Alan;
Hamilton, Matthew Michael; Haynes, Nancy-Ellen; Kowalczyk, Agnieszka; Mayweg, Alexander; Myers, Michael Paul; Fotiadou-Cole, Sherrie Lynn; Scott, Nathan Robert; Thakkar, Kshiti; Chhabilbai; Tilley, Jefferson Wright
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 126pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070049432	A1	20070301	US 2006-507080	20060818
AU 2006286568	A1	20070308	AU 2006-286568	20060821
CA 2618857	A1	20070308	CA 2006-2618857	20060821
WO 2007026892	A1	20070308	WO 2006-JP16498	20060821
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP 1924563	A1	20080528	EP 2006-792932	20060821
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
KR 20080040047	A	20080507	KR 2008-7007590	20080328
PRIORITY APPLN. INFO.:			US 2005-713901P	P 20050901
			US 2006-617255P	P 20060629
			WO 2006-EP65498	W 20060821

OTHER SOURCE(S): MARPAT 146:295915
GI



AB Title compds. I [R1 = aryl, heteroaryl, aralkyl, etc. (wherein aryl, heteroaryl or aralkyl is unsubstituted or substituted with halo, alkyl, alkoxy, etc.; R2 = Ph (optionally substituted with halo, hydroxy, haloalkyl, etc.), (un)substituted naphthyl, biphenyl (optionally substituted with acetyl, halo, alkoxy, etc.), etc.] were prepared for example, reaction of phenylbromo oxychloride with phenylhydrazine and (2S,4R)-camphorcarboxylic acid Et ester followed by methylation using Me iodide afforded compound I [R1 = methyl; R2 = phenyl]. In 11β-HSD1 [11β hydroxysteroid dehydrogenase 1] inhibition assays, compound I [R1 = methyl; R2 = phenyl] showed the IC50 value of 0.067 μM. Compds. I are claimed useful for the treatment of diabetes, obesity, etc.

IT 928051-61-0P 928051-62-1P 928051-63-2P
928051-64-3P 928051-65-4P 928051-66-5P
928051-67-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase for treatment of diabetes and obesity)

RN 928051-61-0 CAPLUS
CN 4,7-Methano-3H-indazol-3-one,
2-[1,1'-biphenyl]-3-yl-1,2,4,5,6,7-hexahydro-
1,7,8,8-tetramethyl-, (4S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 928051-62-1 CAPLUS
CN 4,7-Methano-3H-indazol-3-one, 2-[2'-chloro[1,1'-biphenyl]-3-yl]-
1,2,4,5,6,7-hexahydro-1,7,8,8-tetramethyl-, (4S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 928051-63-2 CAPLUS
CN 4,7-Methano-3H-indazol-3-one, 1,2,4,5,6,7-hexahydro-2-[2'-methoxy[1,1'-biphenyl]-3-yl]-1,7,8,8-tetramethyl-, (4S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 928051-64-3 CAPLUS
CN 4,7-Methano-3H-indazol-3-one,
1,2,4,5,6,7-hexahydro-1,7,8,8-tetramethyl-2-
[2'-methyl[1,1'-biphenyl]-3-yl]-, (4S,7R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 928051-65-4 CAPLUS
CN 4,7-Methano-3H-indazol-3-one, 2-(2'-acetyl[1,1'-biphenyl]-3-yl)-
1,2,4,5,6,7-hexahydro-1,7,8,8-tetramethyl-, (4S,7R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 928051-66-5 CAPLUS
CN 4,7-Methano-3H-indazol-3-one, 1,2,4,5,6,7-hexahydro-2-[3'-methoxy[1,1'-biphenyl]-3-yl]-1,7,8,8-tetramethyl-, (4S,7R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 928051-67-6 CAPLUS
CN 4,7-Methano-3H-indazol-3-one,
1,2,4,5,6,7-hexahydro-1,7,8,8-tetramethyl-2-
[3'-methyl[1,1'-biphenyl]-3-yl]-, (4S,7R)- (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 2007:33976 CAPLUS
DOCUMENT NUMBER: 146:142511
TITLE: Preparation of novel indolecarboxamides as IKK2 inhibitors
INVENTOR(S): Deng, Jianghe; Kerns, Jeffrey K.; Jin, Qu; Lin, Guoliang; Lin, Xichen; Lindemann, Michael; Hnip, Christopher E.; Nie, Hong; Thomas, Sonia M.; Widdowson, Katherine L.
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 396pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007005534	A2	20070111	WO 2006-US25402	20060628
WO 2007005534	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006266028	A2	20070111	AU 2006-266028	20060628
CA 2613066	A1	20070111	CA 2006-2613066	20060628
EP 1896414	A2	20080312	EP 2006-785861	20060628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
MX 2007016541	A	20080307	MX 2007-16541	20071218
KR 2008021077	A	20080306	KR 2007-736656	20071228
NO 2008000457	A	20080129	NO 2008-457	20080124
PRIORITY APPLN. INFO.:			US 2005-695256P	P 20050630
			WO 2006-US25402	W 20060628

OTHER SOURCE(S): MARPAT 146:142511
GI



I



II

AB The title compds. I [R1 = XYZ, tetrahydroisoquinolinyl, dihydroisoindolyl; X = (un)substituted Ph, heteroaryl, etc., Y = a bond or alkylene; Z = NR4R5 or heterocycloalkyl; R2, R3 = H, F, Cl; R4 = H, alkyl (optionally substituted with one hydroxy or one methoxy group); R5 = H, heterocycloalkyl, alkoxy, etc.; U = a bond, alkylene or alkenylene; V = Ph, 5-6 membered heteroaryl, 5-7 membered heterocycloalyl, etc.] which are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease), were prepared e.g., a multi-step synthesis of II, starting from indoline, was given. Selected compds. I were tested for activity against IKK2 (data given for representative compds. I). The invention is further directed to pharmaceutical compns. containing a compound I. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound I or a pharmaceutical composition comprising a compound I.

IT 918341-30-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel indolecarboxamides as IKK2 inhibitors)

RN 918341-30-9 CAPLUS

CN 1H-Indole-7-carboxamide, 3-[3-(ethylsulfonyl)-4-piperidinyl]-5-[3-(1H-pyrazol-1-yl)phenyl]- (CA INDEX NAME)





ACCESSION NUMBER: 2007:14431 CAPLUS
DOCUMENT NUMBER: 146:121962
TITLE: Pyrazole based LXR modulators and their preparation, pharmaceutical compositions containing a compound I, and use in the treatment of diseases
INVENTOR(S): Busch, Brent B.; Platt, Brenton T.; Gu, Xiao Hui; Martin, Richard; Mohan, Raju; Nyman, Michael Charles; Schweiger, Edelly Stevens, William C., Jr.; Wang, Tie Lin; Xie, Yimong
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 533pp., which
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002359	A2	20070104	WO 2006-US24749	20060626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006262846	A1	20070104	AU 2006-262846	20060626
CA 2613517	A1	20070104	CA 2006-2613517	20060626
EP 1913007	A2	20080416	EP 2006-785558	20060626
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
NO 2008000391	A	20080319	NO 2008-391	20080121
KR 2008029844	A	20080402	KR 2008-703957	20080124
PRIORITY APPLN. INFO.:			US 2005-694572P	P 20050627
			US 2005-736120P	P 20051110
			WO 2006-US24749	W 20060626

OTHER SOURCE(S): MARPAT 146:121962
GI

' STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT '

AB Compds. of the invention, such as compds. of formulas I, II, III, and IV and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors. Pharmaceutical compns. containing the compds. and methods of using the compds

are also disclosed. Compds. of formulas I - IV wherein R1 is (un)substituted (hetero)aryl, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted (thio)ethers, etc.; R2 and R21 are independently (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkyldiyl,

R, halo, NO2, CN, (hetero)aryl, etc.; R3 is(un)substituted alkyl, (un)substituted alkyldiyl, (un)substituted alkenyl, (un)substituted acetyl, (un)substituted thioacetyl, etc.; G is (un)substituted (hetero)aryl, (un)substituted biaryl, (un)substituted alkenoyl, etc.; and their pharmaceutically acceptable salts, isomers, and prodrugs thereof, are claimed. Example compd. V was prepd. by acylation of 2-acetyl-5-bromothiophene with Et trifluoroacetate; the resulting 1-[5-bromothien-2-yl]-4,4,4-trifluorobutane-1,3-dione underwent cyclization with 2,5-dichlorophenylhydrazine hydrochloride to give 5-[5-bromothien-2-yl]-1-(2,5-dichlorophenyl)-3-trifluoromethyl-1H-pyrazole, which underwent Suzuki cross-coupling with 3-aminosulfonylphenylboronic acid to give compd. II. All the invention compds. were evaluated for their LXR modulatory activity. From the assay,

it was detd. that several of the tested compds. exhibited IC50 values of <

1 μM.

IT 918316-00-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles as LXR modulators and their use in the treatment of diseases)

RN 918316-00-4 CAPLUS

CN 1H-Pyrazole, 1-[3'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]-3-(trifluoromethyl)-5-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1005577 CAPLUS
DOCUMENT NUMBER: 145:377567
TITLE: Substituted aryl and heteroaryl derivatives
INVENTOR(S): Stolnack, John E.; Kozarek, Keith G.; Parmee, Emma R.
Tata, James R.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 102pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006102061	A2	20060928	WO 2006-US9694	20060317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
AU 2006227435	A1	20060928	AU 2006-227435	20060317
CA 2600119	A1	20060928	CA 2006-2600119	20060317
EP 1863755	A1	20071212	EP 2006-739723	20060317
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007CN03812	A	20071221	IN 2007-CN3812	20070903
CN 101144762	A	20080319	CN 2006-80009887	20070920
PRIORITY APPLN. INFO.:			US 2005-663849P P	20050321
			WO 2006-US9694 W	20060317

OTHER SOURCE(S): MARPAT 145:377567
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The compds. I [A = 6-10 membered aryl or heteroaryl containing 1-2 N atoms, or 6 membered aryl fused to a 5-8 membered carbocyclic ring; R1 = halo, OH, carboxy, carboxyalkyl, CN, nitro, amino, aminoalkyl, alkylcarbamide, (un)substituted alkyl, alkoxy, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, etc.; each R2 = H, halo, OH, carboxy, carboxyalkyl, CN, nitro, amino, aminoalkyl, alkylcarbamide, etc.; R3 = O, S, CR2, alkyl, alkoxyl, aryl, (un)substituted heteroaryl, etc.; R4 = CR2CR2CO2R6, CR2C(R10)CO2R6, or 5-tetrazolyl; R5 = H or halo, OH, carboxy, carboxyalkyl, CN, nitro, amino, aminoalkyl, alkylcarbamide, etc.; R6 = H or alkyl; were prepared for treating type 2 diabetes and related conditions.

L16 ANSWER 13 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:988349 CAPLUS
DOCUMENT NUMBER: 145:293091
TITLE: Preparation of bicyclic heteroaromatic derivatives as anticancer agents
INVENTOR(S): Kauffman, Goar Stryker; Li, Chao; Lippa, Blaise Scott;
Morris, Joel; Pan, Gonghua
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 152pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090241	A1	20060831	WO 2006-IB406	20060215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
CA 2598956	A1	20060831	CA 2006-2598956	20060215
EP 1858902	A1	20071128	EP 2006-710461	20060215
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2005-656457P P	20050224
			WO 2006-IB406 W	20060215

OTHER SOURCE(S): MARPAT 145:293091
GI

AB The title compds. I [X, Y, V and W = N or CR1 (R1 = H, halo, CN, etc.); R4

L16 ANSWER 12 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Thus, compd. II was prepd. from 5-bromo-2-hydroxybenzaldehyde via intermediate III by Suzuki coupling reaction. The ability of the compds. of the present invention to inhibit the binding of glucagon and their utility in treating and preventing type 2 diabetes mellitus was demonstrated in Glucagon Receptor Binding Assay.

IT 910816-74-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of β-alanine derivs. for treating type 2 diabetes and related conditions)

RN 910816-74-9 CAPLUS
CN β-Alanine, N-[4-[2-[3-[3H-pyrazol-1-yl]-4''-(trifluoromethoxy)[1,1':4',1''-terphenyl]-2''-yl]ethyl]benzoyl]- (9CI)

(CA INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 13 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
= H, alkyl, (CR11LR12)t(aryl), (CR11LR12)t(4-10 membered heterocyclyl); R5 = H, alkyl, or R4 and R5 are taken together to form an oxo moiety; R6 and R7 are taken together to form a 4-10 membered (bi)cyclic or hetero(bi)cyclic ring system; R represents a fused 5-6 membered arom. ring comp. 5-2 heteratoms; with provisos], useful for treating abnormal cell growth in mammals (no egentific data given), were prepd. Thus, reacting 4-chloro-7H-pyrrolo[2,3-d]pyrimidine with tert-Bu 5-chloro-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate followed by deprotection afforded II. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compds. I and to pharmaceutical compns. for treating such disorders which contain the compds. I.

IT 908281-64-1P 908281-66-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic heteroarom. derivs. as anticancer agents)

RN 908281-64-1 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 5-[3-[3,5-dimethyl-1H-pyrazol-1-yl]phenyl]-1,2-dihydro-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)

RN 908281-66-3 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 1,2-dihydro-5-[3-(1H-pyrazol-1-yl)phenyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



II

AB Novel compds. and methods of using those compds. for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases

characterized by hypervascularization are provided. In a preferred embodiment, the compds. of the invention modulate the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein. The compds. of the invention I have general formula [X1-(X2)n-A-NH-L-NH-D-(E)q-(F)r]-Q wherein X1 = aryl, heteroaryl, and heterocyclyl; X and Y = individually O, S, alkynyl, alkenyl, etc.; A = an aromatic, monocyclo-heterocyclo, or bicyclo-heterocyclic ring; D = Ph or a 5-6-membered heterocyclic ring; E = Ph, pyridinyl, or pyrimidinyl; L = -C(O)- or -S(O)2-; n,m,q,t = 0-1; and Q = a substituted ring or ring system. Over 300 compds. were prepared. For example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester provided the propionate, which was subsequently converted to the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentanenitrile afforded the 3-[3-(3-tert-butyl-5-amino-1H-pyrazole-1-yl)phenyl]propionate, which was coupled with 1-naphthyl isocyanate and reduced to provide urea II. In a competition assay with BAY 86092 as a fluorescent probe, II inhibited p38 MAP kinase with IC50 of 45 nM.

IT 725684-39-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazolyl aryl ureas as modulators of protein kinase activation state for treatment of inflammation and hyperproliferative diseases)

RN 725684-39-5 CAPLUS

CN 1H-Pyrazol-5-amine, 1-[1,1'-biphenyl]-3-yl-3-(1,1-dimethylethyl)- (CA INDEX NAME)

IT 725684-40-8P, 1-[3-tert-Butyl-1-(3-phenylphenyl)-1H-pyrazol-5-yl]-

3-phenylurea 725684-41-9P, 1-[3-tert-Butyl-1-(3-phenylphenyl)-1H-pyrazol-5-yl]-3-(4-chlorophenyl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; prepn. of pyrazolyl aryl ureas as modulators of protein kinase activation state for treatment of inflamation and hyperproliferative diseases)

RN 725684-40-8 CAPLUS

CN Urea,

N-[1-[1,1'-biphenyl]-3-yl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)



RN 725684-41-9 CAPLUS

CN Urea,

N-[1-[1,1'-biphenyl]-3-yl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



L16 ANSWER 14 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:765253 CAPLUS

DOCUMENT NUMBER: 145:211037

TITLE: Preparation of pyrazolyl aryl ureas as modulators of the protein kinase activation state for treatment of inflammation and hyperproliferative diseases

INVENTOR(S): Flynn, Daniel L.; Petillo, Peter A.

PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, LLC, USA

SOURCE: PCT Int. Appl., 395pp.

CODEN: PIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004093904	A2	20041104	WO 2005-US14597	20050223
WO 2004093904	A3	20061123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005325476	A1	20060803	AU 2005-325476	20050223
CA 2592116	A1	20060803	CA 2005-2592116	20050223
EP 1836173	A2	20070926	EP 2005-857649	20050223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20060117967	A1	20060615	US 2005-367740	20050221
PRIORITY APPLN. INFO.:			US 2004-638987P	P 20040223
			US 2004-638988P	P 20040223
			US 2004-639096P	P 20040223
			US 2004-639987P	P 20040223
			US 2005-318399	B1 20050223
			WO 2005-US7597	W 20050223

OTHER SOURCE(S): MARPAT 145:211037

GI

L16 ANSWER 15 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:605389 CAPLUS
DOCUMENT NUMBER: 145:85802
TITLE: Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts
INVENTOR(S): Leclerc, Margarete K.; Bei, Xiaohong; Longmire, James; Diamond, Gary M.; Shoemaker, James A. W.; Lapointe, Anne M.; Ackerman, Lily
PATENT ASSIGNEE(S): Symyx Technologies, Inc., USA
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006061216	A2	20060622	WO 2005-US45766	20051216
WO 2006061216	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20060235713 A1 20061022 US 2005-305426 20051216
PRIORITY APPLN. INFO.: US 2004-636555P P 20041216

OTHER SOURCE(S): MARPAT 145:85802
GI

L16 ANSWER 15 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 893396-98-0 CAPLUS
CN [1,1'-Biphenyl]-2-ol, 5-(1,1-dimethylethyl)-3-[3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)

RN 893397-03-2 CAPLUS
CN [1,1'-Biphenyl]-2-ol, 5-(1,1-dimethylethyl)-3-(3-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)

RN 893397-08-7 CAPLUS
CN [1,1'-Biphenyl]-2-ol, 5-(1,1-dimethylethyl)-3-(2H-indazol-2-yl)- (CA INDEX NAME)

L16 ANSWER 15 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Ligands, compns., and metal-ligand complexes that incorporate phenol-heterocyclic compds. are disclosed that are useful in the catalysis of transformations such as the polymerization of monomers into polymers. The catalysts have high performance characteristics, including high comonomer incorporation into ethylene/olefin copolymers, where such olefins are for example, 1-octene, propylene or styrene. The catalysts (e.g., I) particularly polymerize styrene to form polystyrene.

IT 893396-93-5P 893396-98-0P 893397-03-0P 893397-08-5P
RL: CAT (Catalyst use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(ligand; production of phenol-heterocyclic ligands and in-situ metal complexes for olefin polymerization catalysts)

RN 893396-93-5 CAPLUS
CN [1,1'-Biphenyl]-2-ol, 5-(1,1-dimethylethyl)-3-(3-methyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



L16 ANSWER 16 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:645826 CAPLUS
DOCUMENT NUMBER: 145:45815
TITLE: Preparation of biaryloxymethylarenecarboxylic acids as antidiabetics.
INVENTOR(S): Gillespie, Paul; Goodnow, Robert Alan, Jr.; Talley, Jefferson Wright
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058648	A2	20060608	WO 2005-EP12555	20051124
WO 2006058648	A3	20061228		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20060122256 A1 20060608 US 2005-283925 20051121
AU 2005331533 A1 20060608 AU 2005-331533 20051124
CA 2589010 A1 20060608 CA 2005-2589010 20051124
EP 1819691 A2 20070822 EP 2005-825551 20051124
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW
CN 101068802 A 20071107 CN 2005-80043223 20051124
JP 2008511646 T 20080424 JP 2007-544787 20051124
NO 20070062608 A 20070621 NO 2007-2608 20070124
MX 2007006584 A 20070615 MX 2007-6584 20070531
IN 2007DN04376 A 20070831 IN 2007-DN4376 20070604
PRIORITY APPLN. INFO.: US 2004-633139P P 20041203
US 2005-715527P P 20050909
WO 2005-EP12555 W 20051124

OTHER SOURCE(S): CASREACT 145:45815; MARPAT 145:45815
GI



AB Title compds. [I; Ar = (hetero)aryl; Ar2 = (substituted) benzo[1,3]dioxol-5-yl, furan-2-yl, isoquinolin-5-yl, isoxazol-4-yl, 1-naphthyl, pyrazol-1-yl, pyrazol-4-yl, pyridin-3-yl, thiophen-2-yl, thiophen-3-yl, R9; R1, R3 = alkyl, alkoxy, CF3, halo, OH, amino, cyano, NO2; R4 = OH, amino and residue; n = 0-6; p, q = 0-2; with provisos], were prepared. Thus, Me 3-(4-iodophenoxymethyl)benzoate, 2-fluoropyridine-5-boronic acid, bis(tricyclohexylphosphine)palladium,

and

K2CO3 were microwaved together in dioxane/H2O at 170° to give after saponification with NaOH 3-[4-(6-fluoropyridin-3-yl)phenoxymethyl]benzoic acid.

The latter at 4.7 μM stimulated glycogen synthase by 209%.

IT 89025-26-9

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of biaryloxymethylarenecarboxylic acids as antidiabetics)

RN 89025-26-9 CAPLUS

CN Benzoic acid, 5-[[[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-4-yl]oxy]methyl]- (CA INDEX NAME)



AB The title compds. I [A = CO2(alkyl), CN, CHO, etc.; X = C or N (if X = N, R4 is absent); Y = a bond, O, CH2NR12, CH2NR12O or OCH2NR12 [R11, R12 = H, alkyl, haloalkyl, etc.]; B = (un)substituted (hetero)aryl; R1-R7 = H, halo, CN, etc.], useful for elevating certain plasma lipid levels, including high d. lipoprotein-cholesterol and for lowering certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly for treating diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans, were prepared and formulated. E.g., a multi-step synthesis of II, starting from 2H-tetrazol-5-amine, was given. Pharmaceutical compns. containing compds. I alone or in combination with other therapeutic agents are disclosed.

IT 888736-59-2P 888736-65-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dibenzylamine compds. for treating diseases exacerbated by low levels of HDL cholesterol, high levels of LDL-cholesterol and triglycerides such as atherosclerosis and cardiovascular diseases)

RN 888736-59-2 CAPLUS

CN 2H-Tetrazol-5-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-N-[[3'-(1H-pyrazol-1-yl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]- (CA INDEX NAME)



ACCESSION NUMBER:	2006:510627 CAPLUS
DOCUMENT NUMBER:	145:27994
TITLE:	Preparation of dibenzylamine derivatives for elevating
	HDL cholesterol
INVENTOR(S):	Chang, George; Didiuk, Mary Theresa; Dorff, Peter Hans; Garuglieri, Kari Shanker; Jaen, Wenhua; Lefker, Bruce Allen; Perry, David Austen; Poppert, Roger Benjamin; Underwood, Toby James
PATENT ASSIGNEE(S):	Pfizer Products Inc., USA
SOURCE:	PCT Int. Appl., 125 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056854	A1	20060601	WO 2005-IB3590	20051121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005306584	A1	20060601	AU 2005-306584	20051121
CA 2589322	A1	20060601	CA 2005-2589322	20051121
EP 1817297	A1	20070815	EP 2005-806456	20051121
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101065366	A	20071031	CN 2005-80044087	20051121
JP 2008508245	T	20080319	JP 2007-542159	20051121
NL 1030486	A1	20060524	NL 2005-1030486	20051122
NL 1030486	C2	20061024		
IN 2007DN03215	A	20070831	IN 2007-DN3215	20070430
KR 2007068213	A	20070702	KR 2007-711611	20070522
MX 2007006137	A	20070719	MX 2007-6137	20070522
NO 2007003025	A	20070820	NO 2007-3025	20070613
PRIORITY APPLN. INFO.:			US 2004-639434P	P 20041123
			US 2005-715617P	P 20050912
			WO 2005-IB3590	W 20051121
OTHER SOURCE(S):	MARPAT 145:27994			
GI				

RN 888736-65-0 CAPLUS

CN 2H-Tetrazol-5-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[[3'-(2,5-dimethyl-2H-pyrazol-3-yl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-2-methyl- (CA INDEX NAME)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:367087 CAPLUS
DOCUMENT NUMBER: 144:412500
TITLE: Preparation of thiazolinobenzoles for treatment and prevention of cancer
INVENTOR(S): Bertenshaw, Body; Brandl, Traxi; Breitfelder, Steffen;
Boschelmy, Ralphy; Gerstberger, Thomas; Gmachl, Michael; Gravert, Matthias; Hilberg, Frank; Hoenke, Christoph; Hofmann, Matthias; Impagnatiello, Maria; Kraller, Dirk; Klein, Christian; Kriat, Bernd; Mayer, Uby; McConnell, Darryl; Kelther, Charlotte;
Schoenerer,
Stefan; Schoog, Andreas; Schweifer, Norbert; Simon, Oliver; Steegmaier, Martin; Steuer, Steffen; Wairenegger, Irene; Weyer-Czernilofsky, Ulrike; Zoegler, Andreas
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004042021	A1	20040520	WO 2003-EP50021	20051005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 10220040877	A1	20040413	DE 2004-10220040877	20041007
DE 10220050813	A1	20060914	DE 2005-10220050813	20050209
AU 2003293609	A1	20040420	AU 2003-293609	20051005
CA 2579295	A1	20060420	CA 2005-2579295	20051005
EP 1739692	A1	20070627	EP 2005-792037	20051005
EP 1739692	B1	20080416		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1Q1035795	A	20070912	CN 2005-80034332	20051005
JP 2008513454	T	20080515	JP 2007-535146	20051005
MX 2007003802	A	20070423	MX 2007-3802	20070329
IN 2007DN03380	A	20070928	IN 2007-DN3380	20070329
KR 2007113188	A	20071128	KR 2007-710385	20070507
PRIORITY APPLN. INFO.:			DE 2004-10220040877A	20041007
			DE 2005-10220050813A	20050209
			EP 2005-107230 A	20050505

WO 2005-EP55021 W 20051005

OTHER SOURCE(S): MARPAT 144:412500
GI



AB Title compds. [I; R1 = NHRc, NHCORc, NHCO2Rc, NHCONRcRc, NHCONRc; R2 = (substituted) alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl; R3 = (substituted) aryl, heteroaryl; Rc = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, etc.], were prepared Thus, title compound I (R1 = AcNH; R2 = cyclohexyl; R3 = 3-pyridinyl) was prepared via cyclocondensation of the corresponding hydrazine and dilactone moieties. I showed EC50's of <5 μM against HCT116 human colon carcinoma cells.

IT 883864-42-4P 883864-43-5P 883864-44-6P
883864-45-7P 883864-46-8P 883864-47-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TEU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolinobenzoles for treatment and prevention of cancer)

RN 883864-42-4 CAPLUS
CN Acetamide, N-[1-[2'-acetyl[1,1'-biphenyl]-3-yl)-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]- (CA INDEX NAME)

RN 883864-43-5 CAPLUS
CN Acetamide, N-[4,5-dihydro-1-[3'-(methylsulfonyl)amino][1,1'-biphenyl]-3-yl]-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]- (CA INDEX NAME)

RN 883864-44-6 CAPLUS
CN Acetamide, N-[4,5-dihydro-1-[4'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-yl]-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]- (CA INDEX NAME)

RN 883864-45-7 CAPLUS
CN Acetamide, N-[1-[2'-(acetylamino)[1,1'-biphenyl]-3-yl]-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]- (CA INDEX NAME)

RN 883864-46-8 CAPLUS
CN Acetamide, N-[1-(3'-fluoro[1,1'-biphenyl]-3-yl)-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]- (CA INDEX NAME)

RN 883864-47-9 CAPLUS
CN Acetamide, N-[4,5-dihydro-1-[3-(1H-indol-5-yl)phenyl]-3-(3-pyridinyl)-1H-pyrazolo[4,3-g]benzothiazol-7-yl]- (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 19 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:369569 CAPLUS
DOCUMENT NUMBER: 144:412533
TITLE: Preparation of substituted 2-aminopyrimidin-4-ones for treating or preventing Aβ-related pathologies
INVENTOR(S): Albert, Jeffrey Scott; Andrisi, Don; Arnold, Jim; Brown, Dean; Callaghan, Owen; Campbell, James; Carr, Robin Arthur Ellis; Chessari, Gianni; Congreve, Miles Stuart; Edwards, Phil; Empfield, James R.; Frederickson, Matjyn; Keether, Gerard M.; Krumrine, Jennifer; Maegor, Russ; Murray, Christopher William; Patel, Sahil; Sylvester, Mark; Thronee, Scott
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astex Therapeutics
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006041404	A1	20060420	WO 2005-SE1533	20051014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1802587	A1	20070704	EP 2005-793318	20051014
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101084199	A	20071205	CN 2005-80043152	20051014
JP 2008514945	T	20080522	JP 2007-536655	20051014
IN 2007DN02531	A	20070803	IN 2007-DN2531	20070404
PRIORITY APPLN. INFO.:			US 2004-619094P	P 20041015
			WO 2005-SE1533	W 20051014

OTHER SOURCE(S): CASREACT 144:412533; MARPAT 144:412533
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I or II [W = C, N; Q = cycloalkyl, cycloalkenyl, aryl, heterocyclyl; R1 = H, halo, alkyl, etc.; Y = NH, O, S, etc.; X, Y, and Z = NR, O, S, etc.; n = 0-3; p, q, r, s, and u = 0-1; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, etc.; with provisos; and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors], useful for treatment

L16 ANSWER 20 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:364842 CAPLUS
DOCUMENT NUMBER: 144:412528
TITLE: Preparation of substituted 2-aminopyrimidin-4-ones for treating or preventing Aβ-related pathologies
INVENTOR(S): Albert, Jeffrey Scott; Andrisi, Don; Arnold, Jim; Brown, Dean; Callaghan, Owen; Campbell, James; Carr, Robin Arthur Ellis; Chessari, Gianni; Congreve, Miles Stuart; Edwards, Phil; Empfield, James R.; Frederickson, Matjyn; Keether, Gerard M.; Krumrine, Jennifer; Maegor, Russ; Murray, Christopher William; Patel, Sahil; Sylvester, Mark; Thronee, Scott
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astex Therapeutics
SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006041405	A1	20060420	WO 2005-SE1534	20051014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1802589	A1	20070704	EP 2005-794248	20051014
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101084198	A	20071205	CN 2005-80043143	20051014
JP 2008514946	T	20080522	JP 2007-536656	20051014
IN 2007DN02535	A	20070803	IN 2007-DN2535	20070404
PRIORITY APPLN. INFO.:			US 2004-619094P	P 20041015
			WO 2005-SE1534	W 20051014

OTHER SOURCE(S): MARPAT 144:412528
GI

AB The title compds. I or II [Q = aryl, heterocyclyl; X = alkylene; q = 0-1; n = 0-2; R1 = H, halo, alkyl, etc.; R2 = H, alkyl, haloalkyl, etc.; R3 = H, alkyl, alkylke, etc.; Ro = H, alkyl, C(O)alkyl, etc.; with provisos; and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors], useful for treatment or prophylaxis of Aβ related pathologies such as cognitive impairment, Alzheimer disease, neurodegeneration and dementia, were prepared E.g., a 2-step synthesis of III, starting from tri-Et phosphonoacetate and 3'-bromoacetophenone, was given. Compds. of the present invention have been shown to inhibit β secretase (including BACE) activity. Generally, the compds. of the present invention have been identified in one or both assays as having an IC50 of 100 uM or less. Pharmaceutical compns. comprising compds. I or II, and methods of their use are disclosed.

L16 ANSWER 19 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
or prophylaxis of Aβ related pathologies such as cognitive impairment, Alzheimer disease, neurodegeneration and dementia, were prepd.

E.g., a 2-step synthesis of III, starting from tri-Et phosphonoacetate and 3'-bromoacetophenone, was given. Compds. of the present invention have been identified in one or both assays as having an IC50 of 100 uM or less. Pharmaceutical compns. comprising compds. I or II, and methods of their use are disclosed.

IT 883889-48-7P 883890-47-9P
RL: PAC (Pharmacological activity); SYN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 2-aminopyrimidin-4-ones for treating or preventing Aβ related pathologies such as cognitive impairment, Alzheimer's disease, neurodegeneration and dementia)

RN 883889-48-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-amino-3-methyl-6-[2-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]ethyl]- (CA INDEX NAME)

RN 883890-47-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-amino-5,6-dihydro-3,6-dimethyl-6-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 20 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

III

IT 883889-48-7P 883890-47-9P
RL: PAC (Pharmacological activity); SYN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 2-aminopyrimidin-4-ones for treating or preventing Aβ related pathologies such as cognitive impairment, Alzheimer's disease, neurodegeneration and dementia)

RN 883889-48-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-amino-3-methyl-6-[2-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]ethyl]- (CA INDEX NAME)

RN 883890-47-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-amino-5,6-dihydro-3,6-dimethyl-6-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Title compds. I [R1 = (un)substituted Ph or heteroaryl; W = N, CH, or CF; Z = O or NH; R2 = H or alkyl; ring A = (un)substituted 5-6 membered heteroaryl], an partimolar II [V = N, CH, or CF; R3 = H, (un)substituted alkyl; R4 = alkyl; ring C = (un)substituted 5-6 membered heteroaryl] are prepared and disclosed as gyrase and/or Topo IV inhibitors. Thus, e.g., III was prepared by cyclocondensation of 1-(3-amino-4-nitro-5-pyrimidin-2-yl)phenyl]-1H-indazole-4-carboxylic acid cyclopropylamide (preparation given) with O,N-diethylcarboxy-2-methyl-2-thiopseudourea (preparation given). In gyrase and in Topo IV inhibition assays, selected compds. of the invention possessed Ki values of less than 50 nM. The present invention relates to methods of treating, preventing, or lessening the severity of bacterial infections in patient. The present invention also relates to methods of using I in combination with one or more addnl. antibacterial agents and/or one or more addnl. therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.

IT 797045-17-9 797045-21-7P 797045-22-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of annulated pyrazoles as gyrase inhibitors)

RN 797045-17-1 CAPLUS

CN Benzamide, 3-[2-[[(ethylamino)carbonyl]amino]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 797045-21-7 CAPLUS

CN Urea, N-[5-(3-cyanophenyl)-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)



RN 797045-22-8 CAPLUS

CN Urea, N-ethyl-N'-[5-[4-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



ACCESSION NUMBER: 2004:192228 CAPLUS
DOCUMENT NUMBER: 144:192243
TITLE: Preparation of annulated pyrazoles as gyrase inhibitors and uses thereof
INVENTOR(S): Charifson, Paul; Deininger, Darryl; Grillot, Anne-Laure; Liao, Yusheng; Konkle, Steven; Stanos, Sean P.; Perola, Emanuele; Wang, Tianzheng; Lefran, Arnaud; Drumm, Joseph
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 219 pp., Cont.-in-part of U.S. Ser. No. 901,928.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060025424	A1	20060202	US 2004-971573	20041021
US 20060122196	A9	20060608		
US 20050038247	A1	20050217	US 2004-901928	20040729
US 20050154176	A1	20050714	US 2004-986549	20041111
PRIORITY APPLN. INFO.:			US 2003-497917P	P 20030715
			US 2003-737638	A1 20031215
			US 2004-901928	A2 20040729
			US 2004-967638	A2 20041129
			WO 2004-US25541	A 20040729
			US 2004-971573	A2 20041021
			WO 2004-US34919	A2 20041021

OTHER SOURCE(S): MARPAT 144:192243
GI

L16 ANSWER 22 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:52454 CAPLUS
DOCUMENT NUMBER: 144:128848
TITLE: Preparation of pyrrolidin-3-yl amines and their use as
as
Histamine-3 agonists and antagonists
INVENTOR(S): Howard, Harry R.; Wlodecki, Bishop
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060014733	A1	20060119	US 2005-156085	20050616
CA 2574761	A1	20060202	CA 2005-2574761	20050707
WO 2006011042	A1	20060202	WO 2005-IB2185	20050707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1771438	A1	20070411	EP 2005-759129	20050707
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008504763	T	20080306	JP 2007-522059	20050707
KR 2007021746	A	20070206	KR 2007-13496	20050707
MX 2006PA14919	A	20070228	MX 2006-PA14919	20061218
PRIORITY APPLN. INFO.:			US 2004-588934P	P 20040719
			WO 2005-IB2185	W 20050707

OTHER SOURCE(S): MARPAT 144:128848
GI



L16 ANSWER 22 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Histamine-3 agonists and antagonists, I, wherein n= 0-7; R1 and R2 are independently selected from the group which includes: H, C1-C6 alkyl; or R1 and R2 together with the carbon to which they are attached form a carbonyl group (C=O) or a 3-8 member ring, wherein from one to three of the carbons in the ring is optionally replaced by O, S, (NR)xsubstituted amine, or C=O, and the ring is optionally fused to a C6-C10 arylene and is optionally substituted at available positions on a ring carbon with one or
two C1-C4 alkyl groups; R3 and R4 are independently selected from the group consisting of H, C1-C8 alkyl optionally substituted with 1 to 4 halogens (especially fluorine) or OH, C3-C7 cycloalkyl, C6-C14 aryl, 3-8 member
heterocyclealkyl optionally substituted with a C1-C4 alkyl-carbonyl group, C6-C10 arylsulfonyl optionally substituted with C1-C2 alkyl, and 5-10 member heteroaryl, or R3 and R4 together with the nitrogen to which they are attached form a 4-7 member ring containing nitrogen (N) and 0-3 heteroatoms selected from N, O, S (e.g., to form azetidine, morpholine, pyrrolidine, piperidine, thiomorpholine); R5 is selected from the group which includes: aryl, heteroaryl, 3-8 member cyclic amine, optionally with
0-3 heteroatoms selected from N, O, or S (e.g., azetidine, pyrrolidine, piperidine, homopiperidine, piperazine, morpholine, thiomorpholine); X is N, P, Cl, Br, I, CH, OR, NRz, CF3, CSF3, (Cl-C6) alkyl, (C1-C6)-alkoxy, (C1-C6alkyl-S(O)q-, wherein q is 0-2. Thus, piperidinyl-benzyl-pyrrolidine II, was prepared from
(S)-[1-[4-(4-piperidinylbenzyl)-pyrrolidin-
3-yl]-dimethylamine and was tested for its ar to human histidine H3 receptors (rat frontal brain H3 binding of Ki= 33 nM). The compds. presented can be used in the treatment of a disorder or condition selected
from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract.
IT 873667-40-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TEU

L16 ANSWER 22 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); FREP (Preparation); USES (Uses)
(prepn. of pyrrolidin-3-yl amines and their use as histamine-3 agonists
and antagonists)
RN 873667-40-4 CAPLUS
CN 3-Pyrrolidinamine, N,N-dimethyl-1-[3'-[(R-pyrazol-1-yl)](1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

L16 ANSWER 23 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1346235 CAPLUS
DOCUMENT NUMBER: 144:88279
TITLE: Preparation of 1-pyrazolyl-3-phenylurea p38 MAP kinase
inhibitors as antiinflammatory medicaments
INVENTOR(S): Flynn, Daniel L.; Petillo, Peter A.
PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 214 pp., Cont.-in-part of U.S. Ser. No. 746,660.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050288286	A1	20051229	US 2004-886032	20040706
US 7202257	B2	20070410		
US 20040180906	A1	20040916	US 2003-746460	20031224
US 7144911	B2	20061205		
US 20070191356	A1	20070816	US 2004-22385	20041223
AU 2005270132	A1	20060209	AU 2005-270132	20050630
CA 2573124	A1	20060209	CA 2005-2573124	20050630
WO 2006014290	A2	20060209	WO 2005-US23100	20050630
WO 2006014290	A3	20060427		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1773784	A2	20070418	EP 2005-768204	20050630
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008505900	T	20080228	JP 2007-520362	20050630
US 20050044488	A1	20050303	US 2004-576708	20040120
US 20070037808	A1	20070215	US 2006-450640	20060609
US 7342207	B2	20080311		
US 20080132506	A1	20080605	US 2006-450653	20060609
PRIORITY APPLN. INFO.:			US 2003-746460	A2 20031224
			US 2002-437304P	P 20021231
			US 2002-437403P	P 20021231
			US 2002-437415P	P 20021231
			US 2002-437487P	P 20021231
			US 2003-463804P	P 20030418
			US 2004-886329	A2 20040706

OTHER SOURCE(S): MARPAT 144:88279
GI



IT

AB Title compds. [R1K]pNA(N0)pin(N0)pDEgYQ [I; wherein R1 = (un)substituted (hetero)aryl; R, Y = independently O, S, NR5, NR5SO2, NR5CO, alkynyl, alkenyl, alkylene, O(CH2)n, N04(CH2)n, wherein for each alkylene, O(CH2)n, one of the methylene groups may be substituted with CO; h = 1-4; A = (un)substituted aryl, hetero(bi)cyclyl; D = (un)substituted Ph, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, thiazolyl, furyl, pyridyl, pyrimidyl; E = (un)substituted Ph, pyridinyl, pyrimidinyl; L = CO, SO2; n, s, p, q, t = independently 0, 1; Q = (un)substituted heterocyclyl, Ph, etc.; R6 = independently H, alkyl, allyl, TMS(CH2)2; with exceptions] were prepared as p38 MAP kinase inhibitors. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the α-C helix, the α-D helix, the catalytic loop, the switch control ligand sequence, or the C-lobe residues of the kinase protein with I [no data]. Although the methods of preparation are not claimed, prepns. and/or characterization data for .apprx.150 examples of I and many intermediates are included. For example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester using 10% Pd/C in EtOH provided the propionate, which was treated with NaNO2 in the presence of 6N HCl and SnCl2•2H2O to give the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentanenitrile in EtOH and 6N HCl afforded Me 3-[3-[3-tert-butyl-1-amino-1H-pyrazole-1-yl]phenyl]propionate. Coupling of the amine with 1-naphthyl isocyanate in CH2Cl2, followed by reduction with LiOH in THF/MeOH/H2O provided the urea II. In a competition assay with SKF 86002 as a fluorescent probe, the latter inhibited p38 MAP kinase with IC50 of 45 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a wide variety of inflammatory conditions [no data].

IT 725686-39-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate preparation of (pyrazolyl)(aryl)urea p38 kinase inhibitors as

RN 725686-39-5 CAPLUS
CN 1H-Pyrazol-5-amine, 1-[3,3'-bipheny1]-3-yl-3-(1,1-dimethylethyl)- (CA INDEX NAME)



IT 725686-40-8P, 1-[3-tert-Butyl-1-(3-phenylphenyl)-1H-pyrazol-5-yl]-3-phenylurea 725686-41-9P, 1-[3-tert-Butyl-1-(3-phenylphenyl)-1H-pyrazol-5-yl]-3-(4-chlorophenyl)urea

RL: PAC (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of (pyrazolyl)(aryl)urea p38 kinase inhibitors as antiinflammatory agents)

RN 725686-40-8 CAPLUS
CN Urea,
N-[3-[1,1'-bipheny1]-3-yl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)



RN 725686-41-9 CAPLUS
CN Urea,
N-[3-[1,1'-bipheny1]-3-yl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 165 THERE ARE 165 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER: 2005:1224305 CAPLUS
DOCUMENT NUMBER: 143:477961
TITLE: Preparation of annulated pyrazoles as gyrase inhibitors and uses thereof
INVENTOR(S): Charifson, Paul S.; Deninger, David D.; Grillot, Anne-Laure; Liao, Tusheng; Konkle, Steven K.; Stanos, Dean; Perola, Emanuele; Wang, Tiansheng; Letiran, Arnaud; Drumm, Joseph
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 212 pp., Cont.-in-part of U.S. Ser. No. 971,573.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050256136	A1	20051117	US 2004-966549	20041011
US 20040235896	A1	20041125	US 2004-967638	20041020
US 20050038247	A1	20050217	US 2004-901928	20040729
US 20060025424	A1	20060202	US 2004-971573	20041021
US 20060122196	A9	20060608		
WO 2006022777	A1	20060302	WO 2004-US34919	20041021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2003-443917P	P 20030131
			US 2004-967638	A2 20041020
			US 2004-901928	A2 20040729
			US 2004-971573	A2 20041021
			WO 2004-US34919	A2 20041021
			US 2003-737638	A1 20031215
			US 2004-982541	A 20041029

OTHER SOURCE(S): MARPAT 143:477961
GI



AB Title compds. I [R1 = (un)substituted Ph or heteroaryl; W = N, CR, or CY; X = CR or CY; Z = O or NH; R2 = H or alkyl; Ring A = (un)substituted 5-6 membered heteroaryl] are prepared and disclosed as gyrase inhibitors. Thus, e.g., II was prepared by cyclocondensation of 1-(3-amino-4-nitro-5-pyridinio-2-ylphenyl)-1H-imidazole-4-carboxylic acid cyclopropylamide (preparation given) with N,N-diethylcarboxy-2-methyl-2-thiopseudourea (preparation given). In gyrase inhibition assays, selected compds. of the invention possessed Ki values of less than 50 nM. The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals. The present invention also relates to methods of using I in combination with one or more addnl. antibacterial agents and/or one or more addnl. therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.

IT 797045-11-1P 797045-21-7P 797045-22-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of annulated pyrazoles as gyrase inhibitors)

RN 797045-11-1 CAPLUS
CN Benzamide, 3-[2-[(ethylamino)carbonyl]amino]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 797045-21-7 CAPLUS
CN Urea, N-[5-(7-cyanophenyl)-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)



RN 797045-22-8 CAPLUS
CN Urea, N-ethyl-N'-[5-[4-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)

ACCESSION NUMBER: 2005:1193587 CAPLUS
DOCUMENT NUMBER: 143:460186
TITLE: Preparation of morpholinylaniline quinazoline derivatives for use as antiviral agents
INVENTOR(S): Spencer, Keith; Dennison, Helena; Matthews, Neil; Barnes, Michael; Chana, Surinder
PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105761	A1	20051110	WO 2005-GB1598	20050428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005238270	A1	20051110	AU 2005-238270	20050428
CA 2564175	A1	20051110	CA 2005-2564175	20050428
EP 1748991	A1	20070207	EP 2005-733731	20050428
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1960345	A	20070418	CN 2005-80013829	20050428
JP 2007534755	T	20071129	JP 2007-510284	20050428
KR 20070011501	A	20070124	KR 2006-723866	20061114
IN 2006DN07016	A	20070831	IN 2006-DN7016	20061124
PRIORITY APPLN. INFO.:			GB 2004-9494	A 20040428
			GB 2004-25268	A 20041116
			WO 2005-GB1598	W 20050428

OTHER SOURCE(S): CASREACT 143:460186; MARPAT 143:460186
GI



AB Title compds. I [wherein R1 - R4 = H, alkyl, haloalkyl, etc., and pharmaceutically acceptable salts thereof] were prepared as antiviral agents. For instance, thermal cyclization of 5-bromo-2-aminobenzoic acid with formamide followed by chlorination with thionyl chloride gave crude 6-bromo-4-chloroquinazoline, which was condensed with 4-morpholinoaniline in refluxing acetonitrile to afford II. This compound showed activity in reducing the replicon level with IC50 of < 5 μM and in reducing the cell ara with TD50 of >25 μM in the cell culture assay using HCV replicon cells #nh 9B. Therefore, I and their pharmaceutical compns. are effective in treating or preventing flaviviridae infections.

IT 869219-05-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of morpholinylaniline quinazoline derivs. for use as antiviral agents)

RN 869219-05-6 CAPLUS
CN 4-Quinazolinamine, N-[4-(4-morpholinyl)phenyl]-6-(3-(1H-pyrazol-1-yl)phenyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L16 ANSWER 26 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1177718 CAPLUS
DOCUMENT NUMBER: 143:440051
TITLE: Biphenyls as histamine-3 receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Howard, Harry R.; Wlodecki, Bishop
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050145543	A1	20051103	US 2005-107457	20050415
CA 2564258	A1	20051110	CA 2005-2564258	20050418
WO 2005105744	A1	20051110	WO 2005-IB1038	20050418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1756058	A1	20070228	EP 2005-718479	20050418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
BR 2005010501	A	20071030	BR 2005-10501	20050418
JP 2007535528	T	20071206	JP 2007-510141	20050418
MX 2006PA12506	A	20061215	MX 2006-PA12506	20061027
			US 2004-564849P	P 20040430
			WO 2005-IB1038	W 20050418

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 143:440051; MARPAT 143:440051
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of compds. of formula I, which are antagonists of histamine H3 receptors. In compds. I, X and Y are independently selected from H, F, Cl, Br, I, optionally F-substituted C1-6 alkyl, optionally F-substituted C1-6 alkoxy, and (C1-6 alkyl)-S(O)p, optionally substituted by F, NO2, COOH, alkoxycarbonyl, or aminocarbonyl, where p is 0, 1, or 2; n and m are independently 1, 2 or 3; R1 and R2 are independently selected from H, (un)substituted C1-8 alkyl, C3-7 cycloalkyl, C6-14 aryl, 3- to 8-membered heterocyclyl, optionally substituted with C1-4 alkylsulfonyl, C6-10 arylsulfonyl, optionally

L16 ANSWER 26 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

substituted with C1-2 alkyl, and 5- to 10-membered heterocyclyl; or R1 and R2, together with the nitrogen to which they are connected, form a 4- to 7-membered ring, where one of the carbons is optionally replaced by O, S, amine, or CO; R3 is selected from optionally halo-substituted C1-8 alkyl, C3-7 cycloalkyl, and C5-14 aryl; R4 is H, or optionally halo-substituted C1-8 alkyl; and R5 is (CR2)t-W, where W is (un)substituted 5- to 7-membered heterocyclyl or heterocyclyl ring and t is 0, 1, or 2. The invention also relates to the prepn. of I, pharmaceutical compns. comprising a compd. of formula I and optionally a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment

of a disorder or condition responding to antagonism of histamine-3 receptors. Reductive amination of 4-(4-bromophenyl)-acetophenone with pyrrolidine followed by sepn. of enantiomers gave optically active amine II. II underwent Suzuki coupling with pyridine-4-boronic acid to give the

corresponding pyridinyl-biphenyl, which was hydrogenated in the presence of platinum(II) oxide resulting in the formation of (R)-4-[4'-[1-(pyrrolidin-1-yl)ethyl]-biphenyl-4-yl]-piperidine (III). Many compds. of the invention express Ki values between 10 and 100 nM, while compd. III has a Ki value of 3.5 nM.

IT 868396-39-7P, 4-(1-(Pyrrolidin-1-yl)ethyl)-4'-(3-(2H-pyrazol-1-yl)phenyl)-biphenyl 868396-75-2P, 4-(1-(Dimethylamino)ethyl)-4'-(3-(pyrazol-1-yl)phenyl)biphenyl

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biphenyls as histamine-3 receptor antagonists)

RN 868396-39-7 CAPLUS
CN 1H-Pyrazole, 3-[4''-[1-(pyrrolidinyl)ethyl][1,1':4',1''-terphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 868396-75-2 CAPLUS
CN [1,1':4',1''-Terphenyl]-4-methanamine, N,N,a-trimethyl-3''-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)

L16 ANSWER 26 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 27 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:638869 CAPLUS
DOCUMENT NUMBER: 143:133700
TITLE: Preparation of peptides as cathepsin cysteine protease inhibitors
INVENTOR(S): Bayly, Christopher; Black, Cameron; Therien, Michel
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061519	A1	20050721	WO 2005-CA7	20050106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2005238292	A1	20050721	AU 2005-238292	20050106
CA 2553726	A1	20050721	CA 2005-2553726	20050106
EP 1706402	A1	20061004	EP 2005-700246	20050106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
CN 1910175	A	20070207	CN 2005-80002080	20050106
JP 2007517918	T	20070705	JP 2006-548051	20050106
IN 2006DN04283	A	20070622	IN 2006-DN4283	20060720
PRIORITY APPLN. INFO.:			US 2004-534920P	P 20040108
			WO 2005-CA7	W 20050106

OTHER SOURCE(S): CASREACT 143:133700; MARPAT 143:133700
GI

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 27 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





AB The invention relates to novel leucinamide derivs. I [X is (CR1R2)0-2; Y, Z are independently CR1R2, O, S, SO2, CO; NR or substituted imino; X, Y are independently un|substituted aryl or heteroaryl; n is 0 or 1; R1, R2 are independently H, halo or (un)substituted alkyl; or CR1R2 is a ring;

R3 is alkyl or alkenyl; R4 is haloalkyl; R5 is H, alkyl, alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, OR, acyl, etc.] or their pharmaceutically-acceptable salts or stereoisomers, which are cathepsin cysteine protease inhibitors useful for treating and preventing cathepsin dependent conditions, e.g., osteoporosis, in which inhibition of bone resorption is indicated. Thus, peptide II was prepared by coupling of N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-4-fluoro-L-leucine with (4S,5R)-4-amino-5-methylhydrofuran-2(3H)-one and (4-methylthiophenyl)acetonitrile, followed by S-oxidation

IT 858945-99-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as cathepsin cysteine protease inhibitors)

RN 858945-99-0 CAPLUS
CN Pentanamide, 4-fluoro-N-[hexahydro-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-4-yl]ethyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 28 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:589416 CAPLUS
DOCUMENT NUMBER: 143:86449
TITLE: Material for organic electroluminescent device, organic electroluminescent device, and illuminating device and display
INVENTOR(S): Otsu, Shingo; Oshiyama, Tomohiro; Katoh, Risako; Kita, Hiroshi
PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005062675	A1	20050707	WO 2004-JP18620	20041214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:			JP 2003-426571	A 20031224
			MARPAT 143:86449	

OTHER SOURCE(S):
GI



AB A material for organic electroluminescent devices is characterized by being
represented by the following general formula (I): (where A1, A2, and A3 independently represent an aromatic carbocyclic group or a heterocyclic group, and C1, C2, and C3 independently represent a residue necessary for forming an aromatic carbocyclic ring or a heterocyclic ring). Also disclosed
are an organic electroluminescent device characterized by using such a

L16 ANSWER 28 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
material for org. electroluminescent devices, a display characterized by comprising such an org. electroluminescent device, and an illuminating device characterized by comprising such an org. electroluminescent device.
IT 855828-27-2
RL: DEV (Device component use); USES (Uses)
(material for organic electroluminescent device, organic electroluminescent
device, illuminating device and display)
RN 855828-27-2 CAPLUS
CN 1H-Pyrazole, 1,1',1''-[pyridylmethylidyne][1,1'-biphenyl]-2,3-diyl]tris-
(9CI) (CA INDEX NAME)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 29 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:651369 CAPLUS
DOCUMENT NUMBER: 143:7714
TITLE: Preparation of substituted triazoles as sodium channel blockers
INVENTOR(S): Park, Min K.; Chakravarty, Prasun K.; Zhou, Bishan; Gonzalez, Edward; Oh, Hyun; Palachi, Brenda; Parsons, William H.; Sisco, Rosemary; Fisher, Michael H.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042076	A2	20050506	WO 2004-US37280	20041105
WO 2005042076	A3	20050922		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004289494	A1	20050506	AU 2004-289494	20041105
CA 2545214	A1	20050506	CA 2004-2545214	20041105
EP 1694654	A2	20060830	EP 2004-800897	20041105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR 2004081839	A	20070109	BR 2004-16319	20041105
CN 1922156	A	20070228	CN 2004-80032935	20041105
JP 2007510741	T	20070426	JP 2006-539729	20041105
US 2006020066	A1	20060126	US 2004-985559	20041110
MX 2006PA05298	A	20060725	MX 2006-PA5298	20060510
IN 2006DN02845	A	20070907	IN 2006-DN2845	20060518
NO 2006002676	A	20060810	NO 2006-2676	20060609
PRIORITY APPLN. INFO.:			US 2003-518969P	P 20031110
			WO 2004-US37280	W 20041105

OTHER SOURCE(S): CASREACT 143:7714; MARPAT 143:7714
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I or II [R1 = H, alkyl, alkenyl, etc.; R2 = H, alkyl; R3, R4 = H, halo, alkyl, etc.; R5-R7 = H, alkoxy, phenoxy, etc.], useful as sodium channel blockers, were prepared E.g., a multi-step synthesis of

L16 ANSWER 30 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:371226 CAPLUS
DOCUMENT NUMBER: 142:430266
TITLE: Preparation of substituted pyrazole ureas for the treatment of inflammation
INVENTOR(S): Clare, Michael; Fletcher, Theresa Zeher; Hampar, Bruce
C.; Hanson, Gunnar A.; Heier, Richard F.; Huang, He; Lennon, Patrick J.; Owens, David R.; Seeking, Matthew T.; Stealey, Michael A.; Wolfson, Serge G.; Xie, Jin
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 429 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037797	A1	20050428	WO 2004-IB3383	20041013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050197328	A1	20050908	US 2004-970769	20041021
PRIORITY APPLN. INFO.:			US 2003-512869P	P 20031021

OTHER SOURCE(S): CASREACT 142:430266; MARPAT 142:430266
GI

AB Title compds. I [X1-2 = C, S, amino; A = cycloalkl(enyl), heterocycloalkyl, etc.; E = hydrido, L2R5; L1-2 = bond, O, SO, etc.; R1 = hydrido, CN, alkyl, alkenyl, etc.; R2-2a-3 = hydrido, OH, amino, etc.; R4 = hydrido, OH, alkoxy, alkyl, etc.; R4 = hydrido, OH, amino, hydroxyalkyl, etc.; R5 =
alkyl, cycloalkyl, cycloalkenyl, etc.] are prepared For instance,

4-[(aminocarbonyl)amino]-1-(4-bromo-3-(trifluoromethyl)phenyl)-1H-pyrazole-

3-carboxamide (II) is prepd. in 5 steps from 6-bromo-3-(trifluoromethyl)aniline, cyanoacetamide, Et bromoacetate and potassium cyanate. II has IC50 = 0.307 uM for hTRK-2. I are useful in the treatment of inflammation, arthritis, cancer, asthma, etc.

IT 850725-41-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted pyrazole ureas for treatment of inflammation)

RN 850725-41-0 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-[3'-(acetylamino)[1,1'-biphenyl]-3-yl]-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



IT 850725-27-9P 850725-29-0P 850725-32-5P
850725-33-6P 850725-34-7P 850725-35-8P
850725-36-9P 850725-37-0P 850725-38-1P
850725-39-2P 850725-40-2P 850725-41-0P
850725-43-2P 850725-44-9P 850725-45-0P
850725-46-1P 850725-47-2P 850725-49-4P
850725-50-7P 850725-56-3P 850725-57-4P
850725-58-5P 850725-59-6P 850725-60-9P
850725-62-1P 850725-63-2P 850725-64-3P
850725-65-4P 850725-66-5P 850725-67-6P
850725-68-7P 850725-69-8P 850725-70-1P
850725-71-2P 850725-72-3P 850725-73-4P
850725-74-5P 850725-75-6P 850725-76-7P
850725-77-8P 850725-78-9P 850725-79-0P
850726-15-7P 850726-40-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrazole ureas for treatment of inflammation)

RN 850725-27-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-fluoro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-29-0 CAPLUS



RN 850725-36-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-37-0 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-(aminomethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-39-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-(4'-amino[1,1'-biphenyl]-3-yl)-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-(cyanomethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-32-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-hydroxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-33-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-34-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-35-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-(3'-amino[1,1'-biphenyl]-3-yl)-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



RN 850725-40-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-[4'-(acetylamino)[1,1'-biphenyl]-3-yl]-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



RN 850725-41-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-43-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 850725-44-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[(methylsulfonyl)amino][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-45-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3-[5-quinolinyl]phenyl]- (CA INDEX NAME)

RN 850725-46-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[anilocarbonyl]amino]-1-[4'-(dimethylamino)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 850725-47-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3-(1,3-benzodioxol-5-yl)phenyl]- (CA INDEX NAME)

RN 850725-49-4 CAPLUS

RN 850725-59-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 850725-60-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[(propylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 850725-62-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-amino-4'-methyl[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 850725-50-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3-(1H-indol-5-yl)phenyl]- (CA INDEX NAME)

RN 850725-54-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(2'-hydroxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

RN 850725-57-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(3'-hydroxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

RN 850725-58-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H-pyrazol-1-yl]- (CA INDEX NAME)

RN 850725-63-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-(aminomethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 850725-64-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 850725-65-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[(cyclopropylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 850725-66-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-[(cyclopropylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 850725-67-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-[(2-

cyanoethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-69-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[[aminocarbonyl)amino]-1-[3'-[(methylamino)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-69-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[[(2-cyanoethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-70-1 CAPLUS
CN Glycine, N-[[3'-[3-[aminocarbonyl)-4-[(aminocarbonyl)amino]-1H-pyrazol-1-yl][1,1'-biphenyl]-4-yl]carbonyl]- (CA INDEX NAME)



RN 850725-71-2 CAPLUS



RN 850725-76-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-acetyl[1,1'-biphenyl]-3-yl)-4-[(aminocarbonyl)amino]- (CA INDEX NAME)



RN 850725-77-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-fluoro-2'-hydroxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-78-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(5'-fluoro-2'-hydroxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-79-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[2'-(cyanoethoxy)-5'-fluoro[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-72-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[2'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-73-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[2'-methoxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850725-74-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-(4'-hydroxy-2'-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 850725-75-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[4'-[(4-oxo-1-piperidinyl)carbonyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 850726-15-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 850726-60-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L16 ANSWER 31 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:140866 CAPLUS
DOCUMENT NUMBER: 142:219280
TITLE: Gyrase inhibitors and uses thereof
INVENTOR(S): Charifson, Paul S.; Deininger, David D.; Grillot, Andrew-Louis; Huang, Yuzheng; Rorkin, Steven M.; Stamos, Dean; Perola, Emanuele; Wang, Tianzheng; Letrian, Arnaud; Drums, Joseph
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 202 pp., Cont.-in-part of U.S. Ser. No. 767,238.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050039247	A1	20050217	US 2004-901928	20040729
US 20040235586	A1	20041125	US 2004-767238	20040129
AU 2004213541	A1	20050210	AU 2004-213541	20040129
CA 2514467	A1	20050210	CA 2004-2514467	20040129
WO 2005012299	A1	20050210	WO 2004-US25141	20040729

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1592686	A1	20051109	EP 2004-7757744	20040129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006526867	T	20061221	JP 2006-532275	20040129
US 20060025424	A1	20060202	US 2004-971573	20041021
US 20060122196	A9	20060608		
AU 2004322641	A1	20060302	AU 2004-322641	20041021
CA 2577758	A1	20060302	CA 2004-2577758	20041021
WO 2006029273	A1	20060302	WO 2004-US34919	20041021

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1769419	A2	20070530	EP 2004-810009	20041021
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV,				
MK	US 20050256136	A1	20051117	US 2004-986549	20041111

L16 ANSWER 32 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

	IN 2005KN01402	A	20060818	IN 2005-KN1402	20050719
	MX 2005PA08126	A	20060330	MX 2005-PA8126	20050729
	WO 2005003345	A1	20050106	WO 2005-US24545	20050706
	KR 2007048762	A	20070509	KR 2007-7000224	20070228
PRIORITY APPLN. INFO.:				US 2003-487917P	P 20030731
				US 2004-767238	A2 20040129
				WO 2004-US2541	A 20040129
				US 2003-737638	A1 20031215
				US 2004-901928	A2 20040729
				US 2004-971573	A2 20041021
				WO 2004-US34919	W 20041021

OTHER SOURCE(S): CASREACT 142:219280; MARPAT 142:219280

AB The present invention relates to the preparation of compds. of formula I [W = N, CR, CF; X = CR, CF; Z = O, NH; R1 = Ph, or heteroaryl ring; R2 = H, or C1-3 alkylalkyl; A = 5-6 membered heteroaryl ring] that inhibit bacterial gyrase and/or Topo IV. Thus, 4-bromo-2,6-difluoroaniline was treated with sodium perborate tetrahydrate in acetic acid to give 5-bromo-1,3-difluoro-2-nitro-benzene which was treated with NaH, and pyrazole to yield 1-(5-bromo-3-fluoro-2-nitro-phenyl)-1H-pyrazole. This pyrazole was reduced using ammonia, and coupled with 3-pyridyl-diethyl borane, followed by reduction using 10% palladium on carbon to give the desired II. These compds., and compns. thereof, are useful in treating bacterial infection.

IT 797045-17-1P 797045-21-7P 797045-22-8P
RL: PAC (Pharmacological activity); PRP (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

L16 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. of bacterial gyrase and/or topoisomerase IV inhibitors as potential antibacterial agents)
RN 797045-17-1 CAPLUS
CN Benzamide, 5-[2-[(ethylamino)carbonyl]amino]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 797045-21-7 CAPLUS
CN Urea, N-[5-[3-(pyrazophenyl)-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)



RN 797045-22-8 CAPLUS
CN Urea, N-ethyl-N'-[5-[4-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)

L16 ANSWER 34 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:123812 CAPLUS
DOCUMENT NUMBER: 142:228240
TITLE: Iridium compound and organic electroluminescent device
INVENTOR(S): using the same
Park, Soo-Jin; Lee, Kwan-Hee; Jung, Dong-Ryun; Shin, Dae-Yup; Kwon, Tae-Hyuk; Hong, Jong-In
PATENT ASSIGNEE(S): Samsung SDI Co., Ltd., S. Korea
SOURCE: U.S. Pat. Appl. Publ., 66 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050031903	A1	20050210	US 2004-912287	20040806
US 7332233	B2	20080219		
KR 2005015811	A	20050221	KR 2003-54778	20030807
KR 1005083059	A	20050822	KR 2004-10414	20040217
JP 2005053912	A	20050303	JP 2004-227907	20040804
CN 1626540	A	20050615	CN 2004-10076658	20040806
PRIORITY APPLN. INFO.:			KR 2003-54778	A 20030807
			KR 2004-10414	A 20040217

OTHER SOURCE(S): MARPAT 142:228240
AB Organometallic compds. are described which comprise a metal, preferably iridium, with ligands including (a) ligand consisting of a(n) (un)substituted Ph ring attached to a(n) (un)substituted five-membered heterocycle having either two nitrogen atoms or a nitrogen and an oxygen atom as the heteroatoms, with the metal being bonded to the heterocycle at a nitrogen and to the Ph ring at a carbon. Organic electroluminescent devices employing the compds., especially devices with emitting layers incorporating them, are also described.

IT 19005-55-1 842162-95-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(iridium complexes and other metal complexes with heteropyridine-containing ligands and organic electroluminescent devices using them)

RN 19005-55-1 CAPLUS
CN 1H-Pyrazole, 1-[1,1'-biphenyl]-3-yl- (CA INDEX NAME)

RN 842162-95-2 CAPLUS
CN 1H-Pyrazole, 1-[1,1'-biphenyl]-3-yl-3-methyl- (CA INDEX NAME)

L16 ANSWER 32 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1019781 CAPLUS
DOCUMENT NUMBER: 142:6535
TITLE: Preparation of benzimidazolyl ureas and related compounds as gyrase inhibitors for treating bacterial infections
INVENTOR(S): Charifson, Paul S.; Deninger, David D.; Grillot, Anne-Laurey; Liao, Yucheng; Rokkis, Steven M.; Stanos, Dony; Perola, Emanuele; Wang, Tiansheng; Lettiri, Arnaud; Druwe, Joseph
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 148 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040235886	A1	20041125	US 2004-767636	20040129
CN 1745077	A	20060308	CN 2004-80003606	20040129
ZA 2005007773	A	20060927	ZA 2005-5773	20040129
US 20050038247	A1	20050217	US 2004-901928	20040729
US 20050256136	A1	20051117	US 2004-986569	20041111
PRIORITY APPLN. INFO.:			US 2003-443911P	P 20030131
			US 2004-767636	A2 20040129
			WO 2004-US2541	A 20040129
			US 2004-901928	A2 20040729
			US 2004-971573	A2 20041021
			WO 2004-US34919	A2 20041021

OTHER SOURCE(S): MARPAT 142:6535
GI



AB The present invention relates to compds. I [W = N, CH, CF; X = CH, CF; I =

L16 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
O, SO2; R1 = (un)substituted Ph, 5-6 membered heteroaryl having 1-3 heteroatoms selected from O, N or S; R2 = H, alkyl; ring A = (un)substituted 5-6 membered heteroaryl having 1-4 heteroatoms selected from N, O or S] which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compns. comprising said compds. E.g., a multi-step synthesis of 1-ethyl-3-[7-[pyridin-2-yl]-5-[pyridin-3-yl]-1H-benzimidazol-2-yl]urea, was given. The compds. I were found to inhibit gyrase and TopoIV with a Ki values of < 50 nM. The compds. I, and compns. thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
IT 797044-17-8P 797044-21-4P 797044-22-5P
797044-23-6P 797044-24-7P 797045-25-8P
797045-17-1P 797045-21-7P 797045-22-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolyl ureas and related compds. as gyrase inhibitors for treating bacterial infections)
RN 797044-17-8 CAPLUS
CN Urea, N-[5-[1,3-benzodioxol-5-yl]-7-[1H-pyrazol-1-yl]-1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)

RN 797044-21-4 CAPLUS
CN Urea, N-[6-[2,2-difluoro-1,3-benzodioxol-5-yl]-4-[1H-pyrazol-1-yl]-1H-benzimidazol-2-yl]-N'-ethyl- (9CI) (CA INDEX NAME)

RN 797044-22-5 CAPLUS
CN Urea, N-ethyl-N'-[5-[4-methoxy-3-[phenylmethoxy]phenyl]-7-[1H-pyrazol-1-yl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)

L16 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 797044-23-6 CAPLUS
CN Urea, N-ethyl-N'-[5-(3-hydroxy-4-methoxyphenyl)-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)

RN 797044-24-7 CAPLUS
CN Urea, N-[5-[2,3-dihydro-1,4-benzodioxin-6-yl]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)

RN 797044-25-8 CAPLUS
CN Urea, N-ethyl-N'-[7-(1H-pyrazol-1-yl)-5-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 797045-17-1 CAPLUS
CN Benzamide, N-[5-[[(ethylamino)carbonyl]amino]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 797045-21-7 CAPLUS
CN Urea, N-[5-[[(cyanoglycyl)-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)

RN 797045-22-8 CAPLUS
CN Urea, N-ethyl-N'-[5-[4-[(2-exo-1-pyrrolidinylmethyl)phenyl]-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)

ACCESSION NUMBER: 2004:902316 CAPLUS
DOCUMENT NUMBER: 141:379921
TITLE: Biaryl-substituted pyrazoles as sodium channel blockers, and their preparation, pharmaceutical compositions, and use in the treatment of pain
INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Tyagarajan, Srirani; Zhou, Bishan
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092160	A1	20041028	WO 2004-US9713	20040330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004230854	A1	20041028	AU 2004-230854	20040330
CA 2520804	A1	20041028	CA 2004-2520804	20040330
EP 1615895	A1	20060118	EP 2004-759062	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1798738	A	20060705	CN 2004-80009516	20040330
JP 2006522150	T	20060928	JP 2006-509477	20040330
IN 2005MN04396	A	20070831	IN 2005-MN4396	20050923
ZA 200508253783	A1	20060817	US 2005-552204	20051003
PRIORITY APPLN. INFO.:			US 2003-460106P	P 20030603
			WO 2004-US9713	W 20040330

OTHER SOURCE(S): MARPAT 141:379921
GI

AB Biaryl-substituted pyrazole compds., which are sodium channel blockers, useful for the treatment of pain and other conditions, are disclosed. The



compds. generally conform to the structure Ar1-Ar2-Ar3 [1) Ar1 = Th with 0-3 selected substituents, typically H, Cl, CF3, OCF3, etc.; Ar2 = 1,3-phenylene, 3,5-, 2,4-, 2,6-, or 4,2-pyridinediyl or 2,6-pyrazinediyl, all with 0-2 selected substituents, typically H, F, OCF3; Ar3 = pyrazol-1-yl or pyrazol-3(5)-yl, with 0-3 selected substituents, typically H, COiPr, CONH2, CO2Me, CO2Et, Me, etc.; including pharmaceutically acceptable salts]. Pharmaceutical compns. comprise an effective amt. of I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treatment of conditions, including acute pain, chronic pain, visceral pain, inflammatory pain, and neuropathic pain, comprise administering an effective amt. of I, either alone, or in combination with one or more therapeutically active compds. I displayed sodium channel blocking activity at concns. ranging from about <0.1 μM to about <50 μM in several described in vitro assays, e.g., in an electrophysiol. assay using an HEK-293 cell line stably expressing the PN1 sodium channel subtype. Approx 300 specific invention compds. were prepd. and listed individually in examples and/or claims. Several preps. are described in detail. For instance, invention compd. II was prepd. in 4 steps. Thus, cyclocondensation of 3-BrC6H4NHNH2.HCl with Et 2,4-dioxovalerate in refluxing AcOH gave 84% Et 1-(3-bromophenyl)-5-methyl-1H-pyrazole-3-carboxylate. Alk. hydrolysis of this ester with 2N NaOH gave 89% of the corresponding acid, which was activated with 1,1-carbonyldiimidazole and amidated with NHMe2 to give 82% 1-(3-bromophenyl)-5-methyl-1H-pyrazole-3-carboxamide. Suzuki coupling of this bromide with 2-CF3OC6H4(CH)2 (prepn. given) gave 88% II.

IT 784140-06-9, Ethyl 5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxylate 784140-20-1P, 5-tert-Butyl-1-[2'-chloro-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxylic acid 784140-20-3P, Ethyl 5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-5-carboxylate 784141-23-7P, 5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-ylmethanol
RL: PAC (Pharmacological activity); PCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of biaryl-substituted pyrazoles as sodium channel blockers, particularly as analgesics)

RN 784140-06-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784140-20-1 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(2'-chloro[1,1'-biphenyl]-3-yl)-5-(1,1-

dimethylethyl)- (CA INDEX NAME)



RN 784140-22-3 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784141-23-7 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



IT 784140-04-1P, 5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784140-05-2P, 5-tert-Butyl-1-(2'-chloro-1,1'-biphenyl-3-yl)-1H-pyrazole-3-carboxamide 784140-07-4P , 5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxylic acid 784140-08-5P, 1-[4'-Fluoro-2'-(trifluoromethyl)-1,1'-biphenyl-3-yl]-5-methyl-1H-pyrazole-3-carboxamide
784140-09-6P 784140-10-9P 784140-11-0P
784140-12-1P 784140-13-2P 784140-14-3P
784140-15-4P 784140-16-5P 784140-17-6P
784140-18-7P 784140-19-8P 784140-21-2P
784140-23-4P 784140-24-5P 784140-25-6P
784140-26-7P 784140-27-8P 784140-28-9P
784140-29-0P 784140-30-3P 784140-31-4P
784140-32-5P 784140-33-6P 784140-34-7P
784140-35-8P 784140-36-9P 784140-37-0P
784140-38-1P 784140-39-2P 784140-40-5P

784140-41-6P 784140-42-7P 784140-43-8P
784140-44-9P 784140-45-0P 784140-46-1P
784140-47-2P 784140-48-3P 784140-49-4P
784140-50-7P 784140-51-8P 784140-52-9P
784140-53-0P 784140-54-1P 784140-55-2P
784140-56-3P 784140-57-4P 784140-58-5P
784140-59-6P 784140-60-9P 784140-61-0P
784140-62-1P 784140-63-2P 784140-64-3P
784140-65-4P 784140-66-5P 784140-67-6P
784140-68-7P 784140-69-8P 784140-70-1P
784140-71-2P 784140-72-3P 784140-73-4P
784140-74-5P 784140-75-6P 784140-76-7P
784140-77-8P 784140-78-9P 784140-79-0P
784140-80-3P 784140-81-4P 784140-82-5P
784140-83-6P 784140-84-7P 784140-85-8P
784140-86-9P 784140-87-0P 784140-88-1P
784140-89-2P 784140-90-5P 784140-91-6P
784140-92-7P 784140-93-8P 784140-94-9P
784140-95-0P 784140-96-1P 784140-97-2P
784140-98-3P 784140-99-4P 784141-00-0P,
5-Methyl-1-[3-(quinolin-8-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-01-1P, 5-Methyl-1-[3-(benzo[b]thien-7-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-02-2P, 5-Methyl-1-[3-(quinolin-6-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-04-4P, 5-Methyl-1-[3-(3-methylquinolin-8-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-05-5P, 5-Methyl-1-[3-(isoquinolin-5-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-06-6P, 5-Methyl-1-[3-(quinolin-5-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-07-7P, 5-Methyl-1-[3-(naphthalen-1-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-08-8P,

5-Methyl-1-[3-[1-(tert-butoxycarbonyl)-1H-indol-5-yl]phenyl]-1H-pyrazole-3-carboxamide 784141-09-9P, 5-Methyl-1-(3',4',5'-trimethoxy-1,1'-biphenyl-3-yl)-1H-pyrazole-3-carboxamide 784141-10-2P, 5-Methyl-1-[2'-(difluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-11-3P, 5-Methyl-1-[3-(2,2-difluorobenzo[1,3]dioxol-4-yl)phenyl]-1H-pyrazole-3-carboxamide 784141-12-4P, 1-(2'-Chloro-1,1'-biphenyl-3-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 784141-13-5P, 3-Amino-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-4-carboxamide 784141-14-6P, 1-(2'-Chloro-1,1'-biphenyl-3-yl)-1H-pyrazole-4-carboxamide 784141-15-7P, 1-(2'-Chloro-1,1'-biphenyl-3-yl)-N-tert-butyl-1H-pyrazole-4-carboxamide 784141-16-8P, 1-(2'-Chloro-1,1'-biphenyl-3-yl)-N-methyl-1H-pyrazole-4-carboxamide 784141-17-9P, 1-(2'-Chloro-1,1'-biphenyl-3-yl)-N-[(2,2'-bithiophen-5-yl)methyl]-1H-pyrazole-4-carboxamide 784141-18-0P, 1-(2'-Chloro-1,1'-biphenyl-3-yl)-N-[4-(trifluoromethoxy)benzyl]-1H-pyrazole-4-carboxamide 784141-19-1P, Ethyl 3-amino-1-[2'-(trifluoromethyl)-1,1'-biphenyl-3-yl)-1H-pyrazole-4-carboxylate 784141-20-4P, 1-[2'-(Trifluoromethyl)-1,1'-biphenyl-3-yl)-1H-pyrazole-4-carboxylic acid 784141-21-5P, 1-[2'-(Trifluoromethoxy)-1,1'-biphenyl-3-yl)-1H-pyrazole-4-carboxylic acid ethyl
ester 784141-22-6P, 3-Amino-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl)-1H-pyrazole-4-carboxylic acid 784141-24-8P, 5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxaldehyde 784141-25-9P, [3-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-5-yl]methanol 784141-26-0P, [5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl methyl ether 784141-27-1P, [5-Methyl-1-[2'-

(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl methanesulfonate 784141-28-2P, [5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]acetonitrile 784141-29-3P, 2-[5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]acetamide 784141-30-6P, 3-(Azidomethyl)-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole 784141-31-7P, 2-Hydroxy-2-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]acetonitrile 784141-32-8P, [5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl methylcarbamate 784141-33-9P, [5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl carbamate 784141-34-0P, [5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl ethylcarbamate 784141-35-1P, [5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl dimethylcarbamate 784141-36-2P, [5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl benzylcarbamate 784141-47-5P, 2-Hydroxy-2-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]acetamide 784141-48-6P, [5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl methyl carbonate 784141-49-7P, [[5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl]amine 784141-50-0P, N-Methoxy-N,5-dimethyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-51-1P, 5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl methyl ketone 784141-52-2P, 5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carbonitrile 784141-53-3P, 3-[5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]-1H-1,2,4-triazole 784141-54-4P, 5-[5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]-1H-tetrazole 784141-55-5P,

4-Bromo-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-56-6P, 4-Bromo-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxylic acid ethyl
ester 784141-57-7P, N-[[5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl]formamide 784141-58-8P, Methyl
3-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]acrylate 784141-59-9P, N-[[5-Methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]methyl]acetamide 784141-60-2P, 2-Methyl-3-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]-2H-1,2,4-triazole 784141-61-3P, 1-Methyl-3-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]-1H-1,2,4-triazole 784141-62-4P, 2-Methyl-5-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]-2H-tetrazole 784141-63-5P, 1-Methyl-5-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]-1H-tetrazole 784141-64-6P, Methyl 3-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]-2,2-dimethylcyclopropanecarboxylate 784141-65-7P, 1-[6-Fluoro-2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-5-methyl-1H-pyrazole-3-carboxamide 784141-66-8P, N-(2-Hydroxyethyl)-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-67-9P, N-(3-Hydroxypropyl)-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-68-0P, N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-69-1P, N,5-Dimethyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-70-4P,

N-Ethyl-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-71-5P, N-[(5-Methyl-1H-1,2,4-triazol-3-yl)methyl]-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-72-6P, N-[(1-Methyl-1H-pyrazol-4-yl)methyl]-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-73-7P, N-[(1H-Pyrazol-3-yl)methyl]-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-74-8P, N-[(1H-1,2,3-Triazol-4-yl)methyl]-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-75-9P, N-[(5-Methyl-2,1,3-oxadiazol-4-yl)methyl]-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-76-0P, N-[(5-Oxo-1,4-dihydro-1,2,4-

triazol-3-yl)methyl]-N,5-dimethyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-77-1P, N-[2-(1-Methylpyrazol-4-yl)ethyl]-N,5-dimethyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-78-2P,

N-[(Thiazol-5-yl)methyl]-5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazole-3-carboxamide 784141-79-3P, 1-[2'-(Trifluoromethoxy)biphenyl-3-yl]-1H-pyrazole-3,5-dicarboxamide 784141-80-6P, Ethyl 3-(aminocarbonyl)-1-[2'-(trifluoromethoxy)biphenyl-3-yl]-1H-pyrazole-5-carboxylate 784141-81-7P, Ethyl 5-(aminocarbonyl)-1-[2'-(trifluoromethoxy)biphenyl-3-yl]-1H-pyrazole-3-carboxylate
784141-82-8P 784141-83-9P 784141-84-0P
784141-85-1P 784141-86-2P 784141-87-3P
784141-88-4P 784141-89-5P 784141-90-8P
784141-91-9P 784141-92-0P 784141-93-1P
784141-94-2P 784141-95-3P 784141-96-4P
784141-97-5P 784141-98-6P 784141-99-7P
784142-00-3P 784142-01-4P 784142-02-5P
784142-03-6P 784142-04-7P 784142-05-8P
784142-06-9P 784142-07-0P 784142-08-1P
784142-09-2P 784142-10-5P 784142-11-6P
784142-12-7P 784142-13-8P 784142-14-9P
784142-15-0P 784142-16-1P 784142-17-2P
784142-18-3P 784142-19-4P 784142-20-7P
784142-21-8P 784142-22-9P 784142-23-0P
784142-24-1P 784142-25-2P 784142-26-3P
784142-27-4P 784142-28-5P 784142-29-6P
784142-30-9P 784142-31-0P 784142-32-1P
784142-33-2P 784142-34-3P 784142-35-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of biaryl-substituted pyrazoles as sodium channel blockers, particularly as analgesics)
RN 784140-04-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-05-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-chloro[1,1'-biphenyl]-3-yl)-5-[3,5-dimethylethyl]- (CA INDEX NAME)



RN 784140-07-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-08-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-09-6 CAPLUS
CN 1H-Pyrazole, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-10-9 CAPLUS
CN 1H-Pyrazole, 3-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-11-0 CAPLUS
CN 1H-Pyrazole, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-12-1 CAPLUS
CN 1H-Pyrazole, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-13-2 CAPLUS
CN 1H-Pyrazole, 3,5-dimethyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-14-3 CAPLUS
CN 1H-Pyrazole, 3,5-dimethyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-15-4 CAPLUS
CN 1H-Pyrazole, 1-[2'-chloro[1,1'-biphenyl]-3-yl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 784140-16-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-chloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-17-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-18-7 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 784140-19-8 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-21-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, methyl ester (CA INDEX NAME)



RN 784140-23-4 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784140-24-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-25-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 3-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-26-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-hydroxy[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-27-8 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 784140-32-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',4'-dichloro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-33-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-34-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-35-8 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 1-(3',5'-dichloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-28-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-(2'-phenoxy[1,1'-biphenyl]-3-yl)- , methyl ester (CA INDEX NAME)



RN 784140-29-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-(2'-phenoxy[1,1'-biphenyl]-3-yl)- , ethyl ester (CA INDEX NAME)



RN 784140-30-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-(2'-phenoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 784140-31-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-formyl[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-36-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3'-fluoro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-37-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-38-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-39-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-[4'-chloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-40-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-fluoro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-41-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3',4'-dichloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-42-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',3'-dimethoxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-43-8 CAPLUS



RN 784140-47-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[1,1':3',1''-terphenyl]-3-yl- (9CI) (CA INDEX NAME)



RN 784140-48-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-[(4-oxo-1-piperidinyl)methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-49-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



CN 1H-Pyrazole-3-carboxamide, 1-(3'-chloro-2'-methyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-44-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(5'-chloro-2'-methoxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-45-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-46-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784140-50-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[1,1'-biphenyl]-3-yl-5-methyl- (CA INDEX NAME)



RN 784140-51-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-(2'-methyl[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 784140-52-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[3-(aminocarbonyl)-5-methyl-1H-pyrazol-1-yl]-2-methyl- (CA INDEX NAME)



RN 784140-53-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(3'-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-54-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-(4'-phenoxy[1,1'-biphenyl]-3-yl)-



RN 784140-55-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3'-chloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-56-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3'-ethoxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-57-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-fluoro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-58-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-ethoxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-63-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-acetyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-64-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3'-acetyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-65-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',3'-dimethyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)

RN 784140-66-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[2-(aminocarbonyl)-5-methyl-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 784140-59-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',4'-difluoro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-60-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',6'-dimethyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-61-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-62-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-67-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-formyl[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-68-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-69-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-70-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-fluoro-6'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-75-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-76-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4'-chloro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-77-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)



RN 784140-74-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[2'-(2,2,2-trifluoroethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-78-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-3-methyl- (CA INDEX NAME)



RN 784140-79-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',3'-dichloro-4-fluoro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-80-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4-fluoro-2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-83-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-fluoro-2'-(trifluoromethoxy)[1,1'-

biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-82-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(5'-fluoro-2'-hydroxy[1,1'-biphenyl]-3-yl)-5-methyl- (CA INDEX NAME)

RN 784140-83-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[5'-(dimethylamino)-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-84-7 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-85-8 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-86-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2'-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-87-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2',3'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-88-1 CAPLUS
CN 1H-Pyrazole, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 784140-93-8 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4'-chloro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-94-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2',3'-dichloro-4-fluoro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-95-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2',6'-dichloro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-96-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2',4'-dichloro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-89-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[3,3-dimethylethyl)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784140-90-5 CAPLUS
CN 1H-Pyrazole, 5-ethoxy-3-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784140-91-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-92-7 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2',3'-dichloro[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-97-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2'-fluoro-6'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784140-98-3 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784140-99-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-chloro-6'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)

RN 784141-00-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(8-quinolinyl)phenyl]- (CA INDEX NAME)



RN 784141-01-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3-benzo[b]thien-7-ylphenyl]-5-methyl- (CA INDEX NAME)



RN 784141-02-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(4-quinolinyl)phenyl]- (CA INDEX NAME)



RN 784141-04-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(3-methyl-8-quinolinyl)phenyl]- (CA INDEX NAME)



RN 784141-08-8 CAPLUS
CN 1H-Indole-1-carboxylic acid, 5-[3-[5-aminoxazolyl]-5-methyl-1H-pyrazol-1-yl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 784141-09-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-10-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[2'-(difluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784141-05-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[3-(5-isoquinolinyl)phenyl]-5-methyl- (CA INDEX NAME)



RN 784141-06-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(5-quinolinyl)phenyl]- (CA INDEX NAME)



RN 784141-07-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-1-[3-(1-naphthalenyl)phenyl]- (CA INDEX NAME)



RN 784141-11-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[3-(2,2-difluoro-1,3-benzodioxol-4-yl)phenyl]-5-methyl- (CA INDEX NAME)



RN 784141-12-4 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-[2'-chloro[1,1'-biphenyl]-3-yl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 784141-13-5 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 3-amino-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784141-14-6 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-[2'-chloro[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-15-7 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-[2'-chloro[1,1'-biphenyl]-3-yl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 784141-16-8 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-[2'-chloro[1,1'-biphenyl]-3-yl]-N-methyl- (CA INDEX NAME)



RN 784141-17-9 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[(2,2'-bithiophen)-5-ylmethyl]-1-(2'-chloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 784141-18-0 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-[2'-chloro[1,1'-biphenyl]-3-yl]-N-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 784141-19-1 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-amino-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784141-20-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784141-21-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784141-22-6 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-amino-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-24-8 CAPLUS
CN 1H-Pyrazole-3-carboxaldehyde, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-25-9 CAPLUS
CN 1H-Pyrazole-5-methanol, 3-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-26-0 CAPLUS
CN 1H-Pyrazole, 3-(methoxymethyl)-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-27-1 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, 3-methanesulfonate (CA INDEX NAME)



RN 784141-28-2 CAPLUS
CN 1H-Pyrazole-3-acetonitrile, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-29-3 CAPLUS
CN 1H-Pyrazole-3-acetamide, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-30-6 CAPLUS
CN 1H-Pyrazole, 3-(azidomethyl)-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-31-7 CAPLUS
CN 1H-Pyrazole-3-acetonitrile, α-hydroxy-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-32-8 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl-, 3-(N-methylcarbamate) (CA INDEX NAME)



RN 784141-33-9 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, carbamate (ester) (9CI) (CA INDEX NAME)



RN 784141-34-0 CAPLUS
CN Carbamic acid, ethyl-, [5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]methyl ester (9CI) (CA INDEX NAME)



RN 784141-49-7 CAPLUS
CN 1H-Pyrazole-3-methanamine, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-50-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-methoxy-N,5-dimethyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-51-1 CAPLUS
CN Ethanone, 1-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 784141-52-2 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-35-1 CAPLUS
CN Carbamic acid, dimethyl-, [5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]methyl ester (9CI) (CA INDEX NAME)



RN 784141-36-2 CAPLUS
CN Carbamic acid, (phenylmethyl)-, [5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]methyl ester (9CI) (CA INDEX NAME)



RN 784141-47-5 CAPLUS
CN 1H-Pyrazole-3-acetamide, α-hydroxy-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-48-6 CAPLUS
CN Carbamic acid, methyl [5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]methyl ester (CA INDEX NAME)



RN 784141-53-3 CAPLUS
CN 1H-1,2,4-Triazole, 5-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 784141-54-4 CAPLUS
CN 2H-Tetrazole, 5-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 784141-55-5 CAPLUS
CN 1H-Pyrazole-3-carboximidic, 4-bromo-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-56-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 4-bromo-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl], ethyl ester (CA INDEX NAME)



RN 784141-57-7 CAPLUS
CN Formamide, N-[[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]methyl]- (CA INDEX NAMES)



RN 784141-58-8 CAPLUS
CN 2-Propenoic acid, 3-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]-, methyl ester (CA INDEX NAMES)



RN 784141-59-9 CAPLUS
CN Acetamide, N-[[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]methyl]- (CA INDEX NAMES)



RN 784141-60-2 CAPLUS
CN 1H-1,2,4-Triazole, 1-methyl-5-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]- (CA INDEX NAMES)



RN 784141-65-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAMES)



RN 784141-66-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAMES)



RN 784141-67-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(3-hydroxypropyl)-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAMES)



RN 784141-68-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[2-hydroxy-3-(hydroxymethyl)ethyl]-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAMES)



RN 784141-63-3 CAPLUS
CN 1H-1,2,4-Triazole, 1-methyl-3-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]- (CA INDEX NAMES)



RN 784141-62-4 CAPLUS
CN 2H-Tetrazole, 2-methyl-5-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]- (CA INDEX NAMES)



RN 784141-63-5 CAPLUS
CN 1H-Tetrazole, 1-methyl-5-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]- (CA INDEX NAMES)



RN 784141-64-6 CAPLUS
CN Cyclopropanecarboxylic acid, 2,2-dimethyl-3-[5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrazol-3-yl]-, methyl ester (CA INDEX NAMES)



RN 784141-69-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N,5-dimethyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAMES)



RN 784141-70-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-ethyl-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAMES)



RN 784141-71-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-N-[3-methyl-1H-1,2,4-triazol-5-yl]methyl]-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAMES)



RN 784141-72-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAMES)



RN 784141-73-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 5-methyl-N-[1H-pyrazol-3-ylmethyl]-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-74-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-N-(1H-1,2,3-triazol-5-ylmethyl)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-75-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-N-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-76-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-N,5-dimethyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-77-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N,5-dimethyl-N-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-78-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-methyl-N-(5-thiazolylmethyl)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-79-3 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-80-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)

RN 784141-81-7 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(aminocarbonyl)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)

RN 784141-82-8 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-83-9 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-84-0 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[5'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-85-1 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(trifluoromethoxy)-5'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-86-2 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(difluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-87-3 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784143-88-4 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[3'-fluoro-6'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-89-5 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[4'-fluoro-2'-[2,2,3,3,3-pentafluoropropoxy][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-90-8 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2',6'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-94-2 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[5'-fluoro-2'-[2,2,3,3,3-pentafluoropropoxy][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-95-3 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[5'-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-96-4 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[4'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-91-9 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-(1-methylethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-92-0 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-[2,2,3,3,3-pentafluoropropoxy)-3'-(trifluoromethoxy][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-93-1 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[2'-[2,2,3,3,3-pentafluoropropoxy)-3'-(trifluoromethyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-97-5 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, N3,N5-diethyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-98-6 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, N3-ethyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784141-99-7 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, 1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-02-3 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxamide, N5-ethyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-03-4 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxylic acid, 1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, 3,5-diethyl ester (CA INDEX NAME)



RN 784142-05-5 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxylic acid, 1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, 3,5-diethyl ester (CA INDEX NAME)



RN 784142-06-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(aminocarbonyl)-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784142-07-0 CAPLUS
CN 1H-Pyrazole-3,5-dicarboxylic acid, 1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, 3-ethyl ester (CA INDEX NAME)



RN 784142-08-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784142-09-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(aminocarbonyl)-1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784142-02-4 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784142-04-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784142-05-8 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-(aminocarbonyl)-1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)





RN 784142-10-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-11-6 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, 3-ethyl 4-methyl ester (CA INDEX NAME)



RN 784142-12-7 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-13-8 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-14-9 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxamide, 5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-15-0 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxamide, 1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-16-1 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxylic acid, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-17-2 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxamide, 5-methyl-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-18-3 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxamide, 1-[2',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-19-4 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[2',5'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-20-7 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxylic acid, 5-methyl-1-[6-(trifluoromethoxy)-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, 4-methyl ester (CA INDEX NAME)



RN 784142-21-8 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxamide, 1-[2',6-bis(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-22-9 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxamide, 5-methyl-1-[6-(trifluoromethoxy)-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-23-0 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl-, diethyl ester (9CI) (CA INDEX NAME)



RN 784142-24-1 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[6-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl-, diethyl ester (9CI) (CA INDEX NAME)



RN 784142-25-2 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-(aminocarbonyl)-1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl-, ethyl ester (CA INDEX NAME)



RN 784142-26-3 CAPLUS

CN 1H-Pyrazole-3,4-dicarboxamide, 1-[6-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-27-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-(aminocarbonyl)-5-[4-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl-, ethyl ester (CA INDEX NAME)



RN 784142-28-5 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxamide, 1-[4-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-29-6 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[4-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-5-methyl- (CA INDEX NAME)



RN 784142-34-3 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 3,5-dimethyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-35-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-amino-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



IT 784142-90-1P, Ethyl 1-(2'-chloro-1,1'-biphenyl-3-yl)-1H-pyrazole-4-carboxylate 784142-91-2P, 1-(2'-Chloro-1,1'-biphenyl-3-yl)-1H-pyrazole-4-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of biaryl-substituted pyrazoles as sodium channel blockers, particularly as analgesics)

RN 784142-90-1 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(2'-chloro[1,1'-biphenyl]-3-yl)-, ethyl ester (CA INDEX NAME)

RN 784142-30-9 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-amino-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784142-31-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 784142-32-1 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-amino-1-[2',4'-bis(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, ethyl ester (CA INDEX NAME)



RN 784142-33-2 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

RN 784142-91-2 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(2'-chloro[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:478773 CAPLUS
DOCUMENT NUMBER: 141:366220
TITLE: Preparation of diaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
INVENTOR(S): Cosford, Nicholas D. P.; Rastnan, Brian W.; Huang, Debing; Smith, Nicholas D.; Tehrani, Lida R.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kaia Rx
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004093793	A2	20041021	WO 2004-US1651	20040130
WO 2004093793	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004228057	A1	20041021	AU 2004-228057	20040130
CA 2520870	A1	20041021	CA 2004-2520870	20040130
EP 1617614	A2	20060111	EP 2004-750171	20040130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1795184	A	20060628	CN 2004-80014567	20040130
JP 2006521414	T	20060928	JP 2006-510074	20040130
IN 2005DN04192	A	20070831	IN 2005-DN4192	20050916
US 20060194927	A1	20060831	US 2005-551709	20051003

PRIORITY APPLN. INFO.: US 2003-4600940 P 20030403
WO 2004-US1651 W 20040130

OTHER SOURCE(S): MARPAT 141:366220
GI

RN 777880-49-9 CAPLUS
CN Pyrimidine, 4-[1-[1,1'-biphenyl]-3-yl-1H-pyrazol-4-yl]- (CA INDEX NAME)

I

II

AB Title compds. represented by the formula I [wherein X, Y = independently (hetero)aryl, and at least one of X and Y is a heteroaryl with N adjacent to the position of attachment to A or B; A, B = independently (hetero)alkyl, alkylsulfonylalkyl, alkylaminoalkyl, etc.; W, Z = independently (un)substituted (hetero)cycloalkyl, alkyl(hetero)aryl; one of A1 and A2 is N, the other is (un)substituted C; R11 = halo, alkyl, alkoxyl, amino(di)alkyl); and pharmaceutically acceptable salts thereof] were prepared as modulators of metabotropic glutamate receptor-5 (mGluR5). For example, reaction of 2-(2-pyridyl)malondialdehyde with hydrazine hydrate (69%), followed by substitution with 1-bromo-3-chloro-5-fluorobenzene (41%) and coupling reaction with pyridin-3-ylboronic acid (80%), gave II. The prepared I were tested for mGluR5 inhibitory activity with IC50 value of about 2 μM in the calcium flux assay. Thus, I and their pharmaceutical compns. are useful as modulators of mGluR5 for the treatment of panic, and bipolar disorder, as well as in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, obesity, drug addiction, drug abuse, drug withdrawal and other diseases (no data).

IT 777880-97-4P 777881-49-9P
RLA PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl pyrazole modulators of metabotropic glutamate receptor-5)

RN 777880-97-4 CAPLUS
CN Pyridine, 2-(1-[1,1'-biphenyl]-3-yl-1H-pyrazol-4-yl)- (CA INDEX NAME)

ACCESSION NUMBER: 2004:589376 CAPLUS
DOCUMENT NUMBER: 141:140453
TITLE: Preparation of 1-pyrazolyl-3-phenylurea p38 MAP kinase inhibitors as antiinflammatory medicaments
INVENTOR(S): Flynn, Daniel L.; Petsilka, Peter A.
PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, Inc., USA; Deciphera Pharmaceuticals, LLC
SOURCE: PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060906	A2	20040722	WO 2003-US39549	20031226
WO 2004060906	A3	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040180906	A1	20040916	US 2003-744640	20031224
CA 2513627	A1	20040722	CA 2003-2513627	20031226
AU 2003303641	A1	20040728	AU 2003-303641	20031226
EP 1585734	A2	20051019	EP 2003-808576	20031226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003293792	A	20051206	BR 2003-17812	20031226
CN 1756749	A	20060405	CN 2003-801820449	20031226
CN 1756747	A	20060405	CN 2003-801100550	20031226
JP 2006514692	T	20060511	JP 2005-508615	20031226
IN 2005CN01638	A	20070302	IN 2005-CN1638	20050628
MX 2005006726	A	20060217	MX 2005-6726	20050630
US 20050245706	A1	20051103	US 2005-124749	20050512
US 20050245531	A1	20051103	US 2005-124750	20050512

PRIORITY APPLN. INFO.:
US 2002-437904P P 20021231
US 2002-437463P P 20021231
US 2002-437471P P 20021231
US 2002-437487P P 20021231
US 2003-463804P P 20030418
US 2003-744640 A 20031224
US 2003-746545 A 20031226

WO 2003-US41449 W 20031226

OTHER SOURCE(S): MARPAT 141:140433
GI



II

AB Title compds. [R1K]rN(R6)pim(NH)pCRgYYQ [I; wherein R1 = (un)substituted (hetero)aryl; R, Y = independently O, S, NR4, NR4SO2, NR4CO, alkynyl, alkenyl, alkylene, O(CH2)n, NR4(CH2)n, wherein for each alkylene, O(CH2)n, and NR4(CH2)n, one of the methylene groups may be substituted with CO; h = 1-4; A = (un)substituted aryl, hetero(bi)cyclyl; D = (un)substituted Ph, pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, pyridinyl; E = (un)substituted Ph, pyridinyl, pyrimidinyl; L = CO, SO2; j, n, s, p, q, t = independently 0, 1; Q = (un)substituted heterocyclyl, Ph, etc.; R6 = independently H, alkyl, alkyl, TMS(CH2)2; with exceptions] were prepared as p38 MAP kinase inhibitors. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the α-C helix, the α-9 helix, the catalytic loop, the switch control ligand sequence, or the C-lobe residues of the kinase protein with I (no data). For example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester using 10% Pd/C in EtOH provided the propionate, which was treated with NaNO2 in the presence of 6N HCl and SnCl2•2H2O to give the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentanenitrile in EtOH and 4N HCl afforded Me 3-(3-(3-tert-butyl-5-amino-1H-pyrazole-1-yl)phenyl)propionate. Coupling of the amine with 1-naphthyl isocyanate in CH2Cl2, followed by reduction with LiOH in THF/MeOH/H2O provided the urea II. In a competition assay with SKF 86002 as a fluorescent probe, the latter inhibited p38 MAP kinase with IC50 of 45 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a wide variety of inflammatory conditions (no data).

IT 725686-39-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intramediate; preparation of (pyrazolyl)(aryl)urea p38 kinase inhibitors as antiinflammatory agents)

RN 725686-39-5 CAPLUS

CN 1H-Pyrazol-5-amine, 1-[1,1'-biphenyl]-3-yl-3-(1,1-dimethylethyl)- (CA INDEX NAME)

ACCESSION NUMBER: 2003:757524 CAPLUS
DOCUMENT NUMBER: 139:276903

TITLE: Preparation of diarylthetrazoles as modulators of metabotropic glutamate receptor-5

INVENTOR(S): Smith, Nicholas D.; Cosford, Nicholas D. P.; Reger, Thomas S.; Rogers, Jeffrey L.; Poon, Steven F.; Huang, Dehua; Chen, Chiayu; Eastman, Brian W.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 170 pp.
CODEN: PIXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003079738	A1	20030925	WO 2003-US7074	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478799	A1	20030925	CA 2003-2478799	20030307
AU 2003213783	A1	20030929	AU 2003-213783	20030307
AU 2003213783	B2	20070125		
EP 1485093	A1	20041215	EP 2003-711474	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005526083	T	20050902	JP 2003-577571	20030307
US 20050153986	A1	20050714	US 2004-506479	20040901
PRIORITY APPLN. INFO.:			US 2002-363458P	P 20020312
			WO 2003-US7074	W 20030307

OTHER SOURCE(S): MARPAT 139:276903
GI



IT 725686-40-9P, 1-[3-tert-Butyl-1-(7-phenylphenyl)-1H-pyrazol-5-yl]-7-phenylurea 725686-41-9P, 1-[3-tert-Butyl-1-(3-phenylphenyl)-1H-pyrazol-5-yl]-3-(4-chlorophenyl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(p-38 kinase inhibitor; preparation of (pyrazolyl)(aryl)urea p38 kinase inhibitors as antiinflammatory agents)

RN 725686-40-9 CAPLUS
CN Urea, N-[1-[1,1'-biphenyl]-7-yl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)



RN 725686-41-9 CAPLUS
CN Urea, N-[1-[1,1'-biphenyl]-3-yl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



I



II

AB Tetrazoles I [A, B = alkylene, optionally interrupted by heteroatoms; X, Y = (un)substituted heteroaryl, at least one of which has N adjacent to the attachment to A or B] are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. I IC50 ≤ 10 μM in the calcium flux assay and ≤ 100 μM in the phosphatidylinositol hydrolysis assay. Thus, 1-(3-aminophenyl)-2-methyl-2-imidazolidinone was diazotized and treated with 2-pyridinecarboxaldehyde and 4-MeC6H4SO2NHNH2 to give the tetrazole II.

IT 605650-93-7P 605652-47-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylthetrazoles as inhibitors of metabotropic glutamate receptor-5)

RN 605650-93-7 CAPLUS
CN Pyridine, 2-[2-[5-fluoro-3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



F

RN 605652-47-9 CAPLUS
CN Pyridine, 2-[2-[2-methoxy-3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-4-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)

L16 ANSWER 37 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 38 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:906233 CAPLUS
DOCUMENT NUMBER: 138:4518
TITLE: Preparation of dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]indole derivatives as prostaglandin D2 receptor antagonists for treatment of allergic rhinitis, nasal congestion, and asthma
INVENTOR(S): Wang, Zhaoyin; Dufresne, Claude; Guay, Daniel; Leblanc, Yves
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.; Beaulieu, Christian
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094830	A2	20021128	WO 2002-CA745	20020522
WO 2002094830	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2447779	A1	20021128	CA 2002-2447779	20020522
AU 2002302248	A1	20021203	AU 2002-302248	20020522
AU 2002302248	B2	20080306		
EP 1395590	A2	20040310	EP 2002-729708	20020522
EP 1395590	B1	20060927		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534774	T	20041118	JP 2002-591503	20020522
AT 340796	T	20061015	AT 2002-729708	20020522
ES 2272712	T3	20070501	ES 2002-729708	20020522
US 20040180934	A1	20040916	US 2003-474929	20031015
US 7144913	B2	20061205		
PRIORITY APPLN. INFO.:			US 2001-293077P P	20010523
			WO 2002-CA745 W	20020522

OTHER SOURCE(S): MARPAT 138:4518
GI

L16 ANSWER 38 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R1, R2, and R3 = independently H, halo, CN, CORa, CO2Ra, CONRaRb, OCONRaRb, SO0-2-(hetero)aryl, NRaSO0-2Rb, NRaRb, NRaCORb, NRaCO2Rb, NRaCONRaRb, SO0-2NRaRb, NO2, cycloalkenyl, or (un)substituted alkyl, alkenyl, alkoxy, heterocyclyl, (hetero)aryl(oxy), or SO0-2-alkyl; Ra and Rb = independently H or (un)substituted alkyl, alkenyl, alkynyl, heterocyclyl, or (hetero)aryl; or NRaRb = heterocyclyl; R4 = H, CN, (halo)alkyl, ORa, or SO0-2-alkyl; R5 = H or (halo)alkyl; or CR4R5 = (un)substituted 3- or 4-membered (hetero)cycloalkyl; R6 = H or (un)substituted alkyl; Ar = (un)substituted (hetero)aryl; A = (un)substituted alkyl; Q = CO2H, CONRaRb, CONHSO2Rc, SO2NHRa, SO2NHRa, SO3H, PO3H2, or tetrazolyl; Rc = (un)substituted alkyl; Y1 = (un)substituted alkylidene optionally interrupted by O, S, NRa, CO, OCO, etc.; Y2 = (un)substituted methylene, ethylene, or ethenylene; and pharmaceutically acceptable salts and hydrates thereof] were prepared as non-steroidal D2 prostaglandin receptor antagonists (no data). For example, 4-[2-bromo-3-(4-chlorobenzyl)-1H-1-indolyl]butanal (4-step preparation given) was coupled with (carbethoxymethylene)triphenylphosphorane to give the Et (E)-2-hexenoate. Cyclization using Bu4NCl, TEA, and Pd(AcO)2 in DMF afforded Et 2-[10-(4-chlorobenzyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-9-yliden]acetate. Reduction with Pd/C (5%, weight/weight) followed by saponification with LiOH in MeOH provided II. I are useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion, and asthma (no data).

IT 476620-21-0P, [9-[(4-Chlorophenyl)thio]-6-fluoro-8-[3-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prostaglandin D2 receptor antagonist; preparation of pyrroloindole and pyridoindole prostaglandin D2 receptor antagonists by cyclization of (indolyl)alkanoates and (indolyl)alkenoates)

RN 476620-21-0 CAPLUS

CN 1H-Pyrrolo[1,2-a]indole-1-acetic acid, 9-[(4-chlorophenyl)thio]-6-fluoro-2,3-dihydro-8-[3-(1H-pyrazol-1-yl)phenyl]- (CA INDEX NAME)

L16 ANSWER 38 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 39 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:833787 CAPLUS
DOCUMENT NUMBER: 137:337786
TITLE: Preparation of chiral alkylaminochroman derivatives as
β3-adrenoreceptor agonists
INVENTOR(S): O'Connor, Stephen J.; Ladouceur, Gaetan H.; Bullock, William H.; Campbell, Ann-Marie; Dai, Miao; Daily, Robert; Dunsa, Jacques; Hatoum-Mokdad, Hoda N.; Khire, Uday; Lee, Wendy Liu, Qingjiey Lowe, Derek B.;
Magnuson, Steven R.; Qi, Ming; Shelekhin, Tatiana E.; Sham, Hing Leung; Smith, Eugene A.; Wang, Ming
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083891	A1	20021031	WO 2002-US12940	20020422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002254717	A1	20021105	AU 2002-254717	20020422
US 20030078249	A1	20030424	US 2002-131448	20020422
US 6660712	B2	20031209		
EP 1395232	A1	20040218	EP 2002-729958	20020422
EP 1395232	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532227	T	20041021	JP 2002-583418	20020422
ES 2230487	T3	20050501	ES 2002-729958	20020422
US 20040078249	A1	20040422	US 2003-664903	20030917
US 6919371	B2	20050719		
US 20050215594	A1	20050929	US 2005-117759	20050428
PRIORITY APPLN. INFO.:			US 2001-285719P	P 20010423
			US 2001-324518P	P 20010926
			US 2002-131448	A1 20020422
			WO 2002-US12940	W 20020422
			US 2003-664903	A3 20030917

OTHER SOURCE(S): MARPAT 137:337786
GI



AB This invention relates to novel 2,6-substituted chroman derivs. which are useful in the treatment of β3-adrenoreceptor mediated conditions. Title compds. I [wherein R = independently OR, =O, halo, CN, NO2, (halo)alkyl, CF3, NR1R2, SR1, OR1, SO2R2, OCOR2, NR1COR2, CO2R1, NR1SO2R2, or (un)substituted Ph or heterocyclyl; R1 = independently H, (CH2)mO(CH2)mR3, or (un)substituted cycloalkyl, Ph, or naphthyl; or NR1R1 = heterocyclyl; R2 = independently H, OR1, NR1R1, or (un)substituted NHSO2-Ph, NHSO2-naphthyl, NHSO2-alkyl, or heterocyclyl; R3 = H, alkyl, or CO2R; R4 = H, alkylphenyl, or alkylpyridyl; R5 = H or CO2R; R6 = H or (un)substituted alkyl or alkyl-SO2-alkyl; Ar = Ph or (fused) heteroaryl; Y = halo, NO2, R6, SR1, SO2-2C6H4CO2H, (CONH4C6H4)pCO2H, or (un)substituted Ph or heterocyclyl; m = 1-3; n = 0-5; p = 1 or 2; and pharmaceutically acceptable salts and esters thereof] were prepared as β3-adrenoceptor agonists. For example, coupling of (2R)-6-iodo-7,8-dihydro-2H-chromene-2-carboxylic acid and (1R)-2-amino-1-(3-pyridinyl)ethanol·2HCl with 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide·HCl, and TEA in CH2Cl2 gave the amide (74%). Reduction using borane-dimethylsulfide complex in THF afforded the chromanmethanamine II (84%). Over one hundred compds. of the invention demonstrated β3-adrenergic receptor agonist activity with EC50 values ≤ 1μM. I are useful in the treatment of β3-adrenergic receptor mediated conditions, including obesity, diabetes, gastrointestinal disorders, cardiovascular disorders, and urinary disorders (no data).

IT 474113-91-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of chiral alkylaminochroman derivs. as β3-adrenoreceptor agonists)

RN 474113-91-2 CAPLUS
CN Carbamic acid, [[(2R)-3,4-dihydro-6-[3-(4-hydroxy-4-methyl-3,5-dioxo-1-pyrazolidinyl)phenyl]-2H-1-benzopyran-2-yl]methyl][(2R)-2-[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(3-pyridinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 39 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 39 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 474113-92-3P, 4-Hydroxy-1-[3-[[2R)-2-[[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]methyl]-3,4-dihydro-2H-chromen-6-yl]phenyl]-4-methyl-3,5-pyrazolidinedione dihydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(β3-adrenoreceptor agonist; preparation of chiral alkylaminochroman derivs. as β3-adrenoreceptor agonists)

RN 474113-92-3 CAPLUS
CN 3,5-Pyrazolidinedione, 1-[3-[[2R)-3,4-dihydro-2-[[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino]methyl]-2H-1-benzopyran-6-yl]phenyl]-4-hydroxy-4-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 40 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:825128 CAPLUS
DOCUMENT NUMBER: 134:94746
TITLE: Metallacyclophanes formed by a tetrapyrazolyl ligand and copper(II) cation
AUTHOR(S): Jouaiti, Abdelaziz; Lou, Marielle; Hosseini, Nar Mekki
De Cian, Andre
CORPORATE SOURCE: Laboratoire de Chimie de Coordination Organique, Universite Louis Pasteur, Strasbourg, F-67000, Fr.
SOURCE: Chemical Communications (Cambridge) (2000), (21), 2085-2086
CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:94746
AB Using 1,2,4,5-tetrakis(pyrazolyl)benzene ligand and CuCl2 or Cu(CF3SO3)2 salts, binuclear metallamacrocycles of cyclophane type were exclusively obtained. Structural characterization of the ligand and both metal complexes is reported. In both complexes, chloride or triflate anions are coordinated to Cu metal centers adopting a square pyramidal coordination geometry.

IT 317808-27-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 317808-27-8 CAPLUS
CN 1H-Pyrazole, 1,1',1'',1'''-[1,1'-biphenyl]-3,3',5,5'-tetrayltetrakis- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1982:627441 CAPLUS
Correction of: 1982:423357
DOCUMENT NUMBER: 97:227441
Correction of: 97:23357
ORIGINAL REFERENCE NO.: 97:37347a,37350a
TITLE: Photographic imaging method
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXAAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 56153336	A	19811127	JP 1980-57269	19800430
JP 63056968	B	19881109		
GB 2077453	A	19811216	GB 1981-12640	19810423
GB 2077453	B	19840111		
DE 3116807	A1	19820108	DE 1981-3116807	19810428
DE 3116807	C2	19940609		
US 4352878	A	19820601	US 1981-259177	19810430
PRIORITY APPLN. INFO.:			JP 1980-57269 A	19800430

OTHER SOURCE(S): MARPAT 97:227441
GI

AB Ag halide photog. materials containing I (R = 1-indazolyl, 2-indazolyl; R1,R2,R3 = H, alkyl, alkylthio, arylthio, halo, OH, alkoxy, aryloxy, acyl, alkoxycarbonyl, amido, sulfonamido, carbamoyl, sulfamoyl, heterocyclic moiety, 1-indazolyl, 2-indazolyl; R4, R5 = H, group hydrolyzed in the presence of an alkali) are developed in the presence of RNHNHCOR' [R6 = aryl; R7 = H, aryl, alkyl]. The method gives high-contrast negatives having excellent halftone characteristics. Thus, p-MeC6H4SO2NHCHO and 2-(5-nitro-2-indazolyl)hydroquinone were added to a AgBr emulsion and the emulsion was coated on a film support. The film was sensitometrically exposed and developed to give a neg. with excellent halftone images.
IT 81927-05-2
RL: DEV (Dev)
(silv halide photog. films containing)
RN 81927-05-2 CAPLUS
CN [1,1'-Biphenyl]-2,5-diol, 3-(5-nitro-2H-indazol-2-yl)- (CA INDEX NAME)

ACCESSION NUMBER: 1982:423357 CAPLUS
DOCUMENT NUMBER: 97:23357
ORIGINAL REFERENCE NO.: 97:4081a,4084a
TITLE: Photographic imaging method
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXAAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 56153336 A		19811127	JP 1980-57269	19800430

GI

AB Ag halide photog. materials containing I (R = 1-indazolyl, 2-indazolyl; R1, R2, R3 = H, alkyl, aryl, alkylthio, arylthio, halo, OH, alkoxy, aryloxy, acyl, alkoxycarbonyl, amido, sulfonamido, carbamoyl, sulfamoyl, heterocyclic moiety, 1-indazolyl, 2-indazolyl; R4, R5 = H, group hydrolyzed in the presence of an alkali) are developed in the presence of RNHNHCOR' [R6 = aryl; R7 = H, aryl, alkyl]. The method gives high-contrast negatives having excellent halftone characteristics. Thus, p-MeC6H4SO2NHCHO and 2-(5-nitro-2-indazolyl)hydroquinone were added to a AgBr emulsion and the emulsion was coated on a film support. The film was sensitometrically exposed and developed to give a neg. with excellent halftone images.
IT 81927-05-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(silv type silver halide photog. films containing)
RN 81927-05-2 CAPLUS
CN [1,1'-Biphenyl]-2,5-diol, 3-(5-nitro-2H-indazol-2-yl)- (CA INDEX NAME)

L16 ANSWER 43 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:226522 CAPLUS
DOCUMENT NUMBER: 96:226522
ORIGINAL REFERENCE NO.: 96:37333a,37336a
TITLE: Photographic development inhibitor-releasing compounds
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 34 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 56113742	A	19811127	JP 1980-17270	19800430
JP 63026377	B	19880530		
US 4345024	A	19820817	US 1981-259278	19810430
US 4501898	A	19850226	US 1982-384809	19820603
PRIORITY APPLN. INFO.:			JP 1980-57270	A 19800430
			US 1981-259278	A3 19810430

OTHER SOURCE(S): MARPAT 96:226522
GI

AB Compds. of formula I (R = 1- or 2-indazolyl; R1, R2, R3 = H, alkyl, aryl, alkylthio, arylthio, halo, OH, alkoxy, aryloxy, acyl, alkoxycarbonyl, amide, sulfonamido, carbamoyl, sulfamoyl, heterocyclic moiety, indazolyl; R2R3 in combination may form a ring; R4, R5 = H, or group which can be hydrolyzed in the presence of an alkali) are used as photog. development inhibitor-releasing compds.
IT 81927-05-1
RL: USES (Uses)
(photog. development inhibitor-releasing compound)
RN 81927-05-1 CAPLUS
CN [1,1'-Biphenyl]-2,5-diol, 3-(5-nitro-2H-indazol-2-yl)- (CA INDEX NAME)

L16 ANSWER 43 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 44 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:15633 CAPLUS
DOCUMENT NUMBER: 94:15633
ORIGINAL REFERENCE NO.: 94:2619a,2619a
TITLE: Heterocyclopolyaromatics. X. The first cyclohexaaromatic compound with 'face-to-face' arrangement of two aromatic ring members
AUTHOR(S): Lexy, Herbert; Kauffmann, Thomas
CORPORATE SOURCE: Org. Chem. Inst., Univ. Muenster, Muenster, D-4400, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1980), 113(8), 2749-54
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 94:15633
GI For diagram(s), see printed CA Issue.
AB The aromatic compound I was prepared in 43% yield by the oxidative coupling with
Cu(II) of the dilithiated compound II. The face-to-face arrangement of the benzene rings in I causes a distinct upfield shift of the NMR signals of the benzene protons.
IT 67673-45-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 67673-45-4 CAPLUS
CN 1H-Pyrazole, 3,3',3'',3'''-[1,1'-biphenyl]-2,2',5,5'-tetrayltetrakis- (9CI) (CA INDEX NAME)



L16 ANSWER 45 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:461288 CAPLUS
DOCUMENT NUMBER: 71:61288
ORIGINAL REFERENCE NO.: 71:11283a,11286a
TITLE: 4-(2-Hydroxyphenyl)-3,5-diphenyl-4H-pyrazolines
AUTHOR(S): Ried, Walter; Wagner, Karl
CORPORATE SOURCE: Univ. Frankfurt/M., Frankfurt/M., Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1969), 724, 155-8
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 71:61288
GI For diagram(s), see printed CA Issue.
AB 3,4,5,2-R1R2[HO]C6HNHNR.HCl (I) (R, R1, and R3 = H or Cl; R2 = H, Cl, Ph, or CO2Et) reacted with ZnCR:CHPh to give 1-[2-(hydroxy-3-(R-substituted)-4-(R1-substituted)-5-(R2-substituted)-6-(R3-substituted)phenyl]-3,5-diphenyl-2-pyrazolines (II). The reaction of I (R = R1 = R2 = R3 = Cl, or R = R2 = R3 = Cl, R1 = H) with ZnCR:CHPh gave 3,4,5,6,2-R1R2R3[HO]C6H3NHN:CPhCR:CHPh, which boiled with AcOH gave the corresponding II. 1,3,5-Triphenyl-2-pyrazolines show fluorescence, but II do not. Acetylation of the OH group of II led to fluorescent derivs.
IT 23286-38-6P 23300-96-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23286-38-6 CAPLUS
CN 4-Biphenylol, 3-(3,5-diphenyl-2-pyrazolin-1-yl)- (8CI) (CA INDEX NAME)

RN 23300-96-1 CAPLUS
CN 4-Biphenylol, 3-(3,5-diphenyl-2-pyrazolin-1-yl)-, acetate (ester) (8CI) (CA INDEX NAME)

L16 ANSWER 46 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:461283 CAPLUS
DOCUMENT NUMBER: 71:61283
ORIGINAL REFERENCE NO.: 71:11293a,11296a
TITLE: Reactions with diazocarbonyl compounds. XXX. 2-Hydroxyphenylhydrazines and their use in pyrazolone syntheses
AUTHOR(S): Kled, Walter; Wagner, Karl
CORPORATE SOURCE: Univ. Frankfurt/M., Frankfurt/M., Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1969), 724, 159-65
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 71:61283
GI For diagram(s), see printed CA Issue.
AB Treatment of 3,4,5,6,2-R3R2R3R4(HO)C6H2- (R, R1, and R3 = H or Cl; R2 = Cl, Ph, NO2H or CO2Et) with Et-Cl2 in HCl, followed by neutralization of the reaction product led to 3,4,5,6,2-R3R2R3R4(HO)C6NHNH2 (I). I (R = R1 = R3 = H, R2 = Cl or Ph) reacted with AcCHClCO2Et to give 4,2-R2(HO)C6-HNHN:CMeCHClCO2Et which upon heating gave 1-[5-hydroxy-5-(R2-substituted)phenyl]-3-methyl-2-pyrazolin-5-ones. I (R, R1, and R3 = H or Cl, R2 = H, Cl, or CO2Et) reacted with Me-CHOC.tplbond.CCO2Me to give 3,4,5,6,2-R3R2R3(HO)C6NHN:C(CO2Me)CH2CO2Me, which upon heating gave 1-[2-hydroxy-3-(R-substituted-4-(R1-substituted)-5-(R2-substituted)-6-(R3-substituted)phenyl]-3-carbomethoxy-2-pyrazolin-5-ones (II).
IT 23280-86-6
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23280-86-6 CAPLUS
CN 2-Pyrazolin-5-one, 1-(4-hydroxy-3-biphenylyl)-3-methyl- (8CI) (CA INDEX NAME)

L16 ANSWER 47 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:431379 CAPLUS
DOCUMENT NUMBER: 69:31379
ORIGINAL REFERENCE NO.: 69:9379a,9382a
TITLE: Molecular orbital calculations of pyrazoles. I. Alkyl- and aryl-pyrazoles
AUTHOR(S): Finar, I. L.
CORPORATE SOURCE: Northern Polytech., London, UK
SOURCE: Journal of the Chemical Society [Section] B: Physical
Organic (1968), (7), 725-32
CODEN: JCSPAC; ISSN: 0045-6470
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The longest π → π* wave absorption band in the uv spectra of 40 alkyl- and arylpyrazoles was calculated by the simple L.C.A.O.M.O. method.
With a suitable choice of parameters, a good correlation was obtained between the calculated and observed frequencies. Angles of twist were calculated for some sterically hindered pyrazoles, and the stabilities of some tautomeric forms of 1-unsubstituted pyrazoles and the basicities of a number of pyrazoles were examined. Electrophilic and homolytic substitution in pyrazole, 1-methyl- and 1-phenylpyrazole, and their corresponding conjugate acids were discussed in terms of reactivity indices. 69 references.
IT 19005-55-1
RL: PRP (Properties)
(conformation and spectrum (uv) of)
RN 19005-55-1 CAPLUS
CN 1H-Pyrazole, 1-[1,1'-biphenyl]-3-yl- (CA INDEX NAME)

L16 ANSWER 48 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:68257 CAPLUS
DOCUMENT NUMBER: 68:68257
ORIGINAL REFERENCE NO.: 68:13143a,13146a
TITLE: Spectroscopic studies of some 1-phenylpyrazole derivatives
AUTHOR(S): Tisar, Ivar L.; Packham, D. M.
CORPORATE SOURCE: Northern Polytech., London, UK
SOURCE: Journal of the Chemical Society [Section] B: Physical
Organic (1968), (2), 211-14
CODEN: JCSPAC; ISSN: 0045-6470
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 1-Phenylpyrazoles were studied by uv, ir, and N.M.R. spectroscopy. The steric effects of substituents and the position of protonation in strongly acidic media are discussed in terms of the changes observed in uv and N.M.R. absorption. A new series of 1-pentafluorophenylpyrazoles was synthesized, and their spectra are compared with those of the parent pyrazoles. Commonly occurring bands in the ir spectra of 1-phenylpyrazoles are tabulated and assignments made. 26 references.
IT 19005-55-1
RL: PRP (Properties)
(nuclear magnetic resonance and spectrum (ir and uv) of)
RN 19005-55-1 CAPLUS
CN 1H-Pyrazole, 1-[1,1'-biphenyl]-3-yl- (CA INDEX NAME)

```
=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                262.56     995.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -38.40     -40.80

STN INTERNATIONAL LOGOFF AT 12:29:03 ON 01 JUL 2008
```